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EPIGENETIC STATES REGULATE TUMOR AGGRESSIVENESS AND 
RESPONSE TO TARGETED THERAPIES IN LUNG ADENOCARCINOMA 
 
 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related 
death worldwide, 85% of which are lung adenocarcinomas (LUAD). Although 
molecular studies of NSCLC identified targetable mutations of some oncogenes 
including BRAF, EGFR and ALK, no targeted therapies exist for most cases. 
Cancer epigenetics is the study of epigenetic modifications, including histone 
modifications, that control gene expression in cancer. Recent advances have 
revealed numerous epigenetic abnormalities in human cancers, and targeting 
epigenetic regulators could be effective at reversing dysregulated epigenetic 
programs or driving sensitivity to other targeted therapies. 
Inhibitors of the histone methyltransferase EZH2 have recently been 
approved as single agents for specific solid tumors including lymphoma and 
sarcoma. In the first project, by using a genetic model to delete Ezh2 in KRAS-
driven LUAD, we observed that Ezh2 haplo-insufficient tumors were less lethal and 
lower grade than Ezh2 full-insufficient tumors, which were poorly differentiated and 
metastatic. By using three-dimensional (3D) cultures and in vivo experiments, we 
identified that EZH2 deficient tumors were vulnerable to H3K27 demethylase and 
BET inhibitors. EZH2 and BET inhibitors also strongly synergized in human lung 
cancer cells. Mechanistically, EZH2 depletion led to de-repression of the 
embryonic transcription factor FOXP2, promoting stemness and migration. In 
human lung cancers, poorly differentiated tumors were enriched for an H3K27me3-
low state. Together these data uncover the role of EZH2 activity in the 
aggressiveness of LUAD and suggest that EZH2 inhibitors will be most effective 
as low dose single therapies or in combination with drugs including BET inhibitors 
for LUAD. In the second project, we observed that the PIK3CA-mutant or amplified 
lung cancer cells were more sensitive to EZH2 inhibition. EZH2 inhibitor had 
combinatorial synergy with PI3K inhibitor in PIK3CA-mutant or amplified lung 
     
 
cancers both in vitro and in vivo.  This study suggested a promising combination 
therapy in combating the LUAD with PIK3CA mutation or amplification. 
Targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase 
inhibitors (TKIs) is one of the major precision medicine options for LUAD. While 
first- and second-generation TKIs were plagued by development of drug resistance, 
third-generation inhibitors including osimertinib and rociletinib were developed. In 
the third project, we describe a model of EGFR driven lung cancer and a method 
to develop tumors of distinct epigenetic states through 3D organotypic cultures. 
We discovered that activation of EGFR T790M/L858R mutation in lung epithelial 
cells can drive lung cancers with alveolar or bronchiolar features, which can be 
originated from alveolar type 2 (AT2) cells or bronchioalveolar stem cells (BASCs), 
but not basal cells or club cells. We also demonstrated that these clones were able 
to retain their epigenetic differences through passaging orthotopically in mice, and 
crucially that they had distinct drug vulnerabilities. This work serves as a blueprint 
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CHAPTER 1. INTRODUCTION 
1.1 Epigenetics and cancer epigenetics 
1.1.1 Chromatin and epigenetics 
Eukaryotic chromatin, located in the nucleus of cells, is a precise compact 
structure of macromolecules within a chromosome.1 It contains DNAs, RNAs and 
histone proteins. The main role of chromatin is to package the long DNA molecules 
into more compressed and denser structures by wrapping the DNAs around the 
histone molecules in tight coil so that to make them fit into the nucleus.2 The 
chromatin is further coiled into condensed chromosome, which is the higher order 
of the DNA organization.3 Chromatin also gets involved in many biological 
processes including transcription regulation and DNA repair through the dynamic 
regulation of chromatin organization.4,5 
The core histone octamer  is composed of four pairs of histone proteins 
H2A, H2B, H3 and H4. Histone H1 is not the core component of the octamer but 
helps stabilize the chromatin fiber between chromosomes.6,7 Histone proteins are 
basic and thus positively charged, which enables them to tightly associate with 
negatively charged DNA molecules.8 The modifications or variant incorporation of 
histone proteins and chromatin remodeling precisely regulate the chromatin 
structure and thus greatly influence the gene expression. 
Epigenetics is the study of gene expression alterations without changing the 
nucleotide sequence.9 Cellular differentiation from embryonic stem cells to 
terminally differentiated cells is an example of normal epigenetic regulation. 
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Epigenetic regulation consists of four main categories: DNA methylation, histone 
modification, nucleosome remodeling and RNA-mediated targeting.10 Addition of 
methyl groups onto DNA strain can result in limited accessibility of transcription 
machinery in a specific genomic region, and thereafter inactivate the gene 
transcription.11,12 Histone tail methylation and acetylation are the major 
posttranscriptional modifications of histone components.13 Others include histone 
phosphorylation, ubiquitylation, sumoylation, O-GlnNAc-glucosamine, ADP 
ribosylation, glycosylation, hydroxylation, proline isomerization, formylation, 
succinylation and citrullination.8 Transferring an acetyl group to the side chain of 
histone tail could neutralize the positive charge of DNA molecule and loosen the 
electrostatic interactions between DNAs and histone octamer, which depresses 
the gene transcription in that genomic region. On the contrary, methylation of the 
histone tail stabilizes the DNA-histone association and suppresses the gene 
expression.14 Enzymes that can write, erase, or read these modifications in the 
histone side chains play an important role in histone-mediated regulation. 
Chromatin remodeling or reorganization is a dynamic alteration of chromatin 
architecture, comprising nucleosome reposition, eviction and histone variant 
replacement.15,16 One of the most important complexes is SWI/SNF chromatin 
remodeling complex, also known as BRG/BRM-associated factor (BAF) complex 
in mammals. SWI/SNF complexes can destabilize histone-DNA interaction and 
remodel chromatin nucleosomes in an ATP-dependent manner to regulate gene 
expression.17-19 Non-coding RNAs and RNA modifications can also mediate 
epigenetic regulation. Non-coding RNAs are the RNA molecules which are not 
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eventually translated into protein, and include microRNAs, short interfering RNAs 
and long non-coding RNAs.20,21 Non-coding RNAs participate in translation, RNA 
splicing, DNA replication and many other biological activities. Moreover, the most 
abundant mRNA post-transcriptional chemical modification in mammals is RNA 
N6-methyladenosine (m6A).22,23 m6A RNA methylation engages in mRNA splicing, 
transportation and stabilization.  
The advances of technologies in studying the epigenetics recent years 
greatly help the understanding of epigenome, not only in the specific genomic 
regions, but also in a larger genome-wide scale. The epigenetic techniques used 
frequently include chromatin immunoprecipitation with sequencing (ChIP-seq), 
assay for transposase-accessible chromatin with sequencing (ATAC-seq), 
bisulfite-sequencing and chromatin conformation capture (3C)-based high-
throughput sequencing (Hi-C) technology.24,25 
1.1.2 Epigenetics in cancer 
Epigenetics plays a pivotal role in the normal physiological function or 
development, and aberrant epigenetic regulation may be engaged in many 
diseases including cancer.26 Recent advances have revealed global epigenetic 
abnormalities in human cancers and reversing the dysregulated epigenetic 
mechanisms could be a potentially effective targeted therapy.11 
The first discovery linking epigenetic aberrations with cancer was identified 
in the DNA hypomethylation in cancers back in 1983. Feinburg and Vogelstein 
found that massive hypomethylation of CpG islands in some genes of cancer cells 
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compared with their normal counterparts in two different cancer types.27 Some 
oncogenes such as HRAS were affected by hypomethylation.28,29 DNA 5-
methylcytosine content was also found to be universally reduced in cancer, and its 
level was intermediate between benign and metastatic lesions.30 Hypermethylation 
of tumor suppressors was first identified in 1989 which showed RB gene 
hypermethylation in retinoblastoma.31-33 Not only local or genome-wide abnormal 
methylation and demethylation of DNA CpG islands, but also the malfunction of 
associated enzymes play an important role in regulating the gene expression in 
cancer. Somatic mutations in these DNA methyltransferase and methylation-
binding proteins contribute to human malignancies. 
Histone modifying enzymes transfer or remove chemical groups to amino-
terminal tails of core histones.34 These modifications could directly regulate the 
accessibility and transcription of the DNA regions around the histone protein, or 
recruit chromatin remodeler or other complexes to re-shape the chromatin 
architecture. Abnormal histone modifications induced by mutations of chromatin-
binding proteins were frequently observed in various types of cancer, which may 
initiate or promote cancer development by disrupting the balance between the 
transcription-activating modifications such as H4K16ac, H3K27ac and H3K4me3 
and transcription-repressing modifications including H3K27me3 and H3K9me3.35 
For example, losses of acetylated Lysine 16 and trimethylated Lysine 20 on 
histone H4 have been described as hallmarks of human cancers.36 Mutations of 
methyltransferase SETD2 which lead to global loss of tri-methylate histone H3 at 
Lysine 36 were also frequently reported in tumor cells.37 
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Mounting evidence shows that components of chromatin remodelers are 
mutated or functionally dysregulated in many cancers, which may reprogram the 
gene expression associated with oncogenes or tumor suppressors. One of the 
most important complexes involved is SWI/SNF complex, also known as 
BRG/BRM-associated factor (BAF) complex in human, can modulate histone-DNA 
interaction and remodel chromatin nucleosomes in an ATP-dependent manner to 
regulate gene expression. 17-19 Its core catalytic subunit BRG1 is frequently 
referred to in the literature as tumor suppressor or tumor susceptibility gene in 
various cancers including NSCLC.38-42 Loss of BRG1/SMARCA4 may promote 
cancer due to genomic instability, abnormal Myc signaling, uncontrolled cell cycle 
or deficits in DNA repair.43-47 However, overexpression of BRG1 without apparent 
mutation emerges as oncogenic mechanisms, which might involve the 
RAS/RAF/MAPK, JNK, PI3K/Akt and Jak/STAT signaling pathways, in leukemia, 
gastric carcinoma, breast cancer, prostate cancer and other cancer types, 
demonstrating the dual faceted functionality of BRG1 in different cellular 
contexts.48 
Only a small number of transcribed genes are eventually translated, and the 
remaining noncoding RNAs are believed to be essential for normal cellular 
functions and their abnormalities potentially contribute to cancer or other 
diseases.49-51 Noncoding RNAs regulate cancer initiation or progression by 
transcriptional and post-translational alterations, chromatin reorganization and 
disrupted signaling transmission. For example, HOX transcript antisense RNA 
(HOTAIR) has been observed amplified in colorectal, lung and breast cancers, 
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mechanistically by coordinating with Polycomb Repressive Complex 2 (PRC2), 
histone demethylase LSD1-containing CoREST/REST complex or other 
microRNAs.52-55 Inhibition of HOTAIR was found to suppress PI3K/AKT/mTOR 
signaling pathway and thus conferred sensitivity to imatinib.56,57 Together, these 
findings demonstrate that various epigenetic regulators are deregulated or 




1.2 Polycomb Repressive Complex 2 and cancer 
1.2.1 Functions of PRC2 
Gene expression is robustly and precisely regulated by transcription factors 
in concert with chromatin-associated modifying complexes. Polycomb group 
proteins, first identified in Drosophila melanogaster and  conserved in mammalian 
cells, play a vital role in this regulating process.58 Polycomb group proteins usually 
assemble and form bulky complexes when exerting their normal functions, which 
can be classified as two main categories, Polycomb Repressive Complex 1 
(PRC1) and Polycomb Repressive Complex 2 (PRC2).59 Canonical and non-
canonical PRC1 both contain the really interesting new gene 1A/B (RING1A/B), 
which has the E3 ubiquitin ligase activity.60,61 PRC1 subunits also include 
Chromobox (CBX) protein, polyhomeotic-like protein (PHC), Polycomb group 
RING finger (PCGF) protein and other subunits depending on the variants.58 The 
function of PRC1 is to mono-ubiquitinate histone H2A at Lys 119 (H2AK119ub). 
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PRC2 core proteins are composed of the enhancer of zeste homologue 2 (EZH2) 
or its paralogue EZH1, embryonic ectoderm development (EED), suppressor of 
zeste 12 (SUZ12) and RB binding protein 4/7 (RBBP4/7).62,63 Recent research also 
identified that there exist four variants of PRC2 combining with different accessory 
components, including elongin BC and PRC2-associated protein (EPOP)-
containing PRC2.1, PRC2-associated ligand-dependent corepressor isoform 1 
(PALI1)-containing PRC2.1, adipocyte enhancer-binding protein 2–Jumonji AT 
rich interactive domain 2 (AEBP2-JARID2)-containing PRC2.2 and Catalytic 
Antagonist of Polycomb (CATACOMB)-containing PRC2 variant.58,64 These 
variants may exert their functions at distinct cellular contexts, although PRC2.1 
and PRC2.2 showed co-occupancy at most target sites.  
Core subunit EZH2 contains a C-terminal SET-domain and acts as the main 
lysine methyltransferase of PRC2, which could mono-methylate, di-methylate, and 
tri-methylate histone H3 at Lysine 27 (H3K27me1, H3K27me2 and H3K27me3) by 
using S-adenosyl methionine (SAM) as the methyl donor.65 EZH1 exhibits much 
weaker methyltransferase activity and may target different downstream genes.66 
EED recognizes and binds to the H3K27me3, stabilizing the catalytic function of 
SET domain. The role of SUZ12 in PRC2 has not yet been completely understood. 
Its zinc-finger may combine with HOTAIR to suppress gene expression.67 
H3K27me3 is the most studied enzymatic substrate of PRC2 because its 
distribution heavily overlaps with PRC2 binding sites. While histone H3 tail with 
H3K27me3 remains positively charged and keeps the negatively charged DNA coil 
tightly packed, loss of methyl groups or addition of acetyl groups to the histone tail 
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(H3K27ac) neutralizes the positive charges, making this genomic region more 
accessible to transcription factors. 
The balance of H3K27 methylation is orchestrated between the writers 
(PRC2 proteins) and erasers (demethylases) of methyl groups. Two major H3K27 
demethylases are the ubiquitously transcribed tetratricopeptide repeat X 
chromosome (UTX/KDM6A) and Jumonji D3 (JMJD3/KDM6B), which can 
discharge methyl groups from H3K27me3 and H3K27me2.68,69 The enzymatic 
function of KDM6A/B is required for cell differentiation, embryonic or tissue 
development and maintenance of the immune system. Abnormalities of H3K27 
demethylases can also contribute to human diseases including cancer.70,71 
 
1.2.2 PRC2 in cancer and epigenetics 
PRC2 exhibits a key role in embryonic development and maintenance of 
cell identity and may act as an oncogene or tumor suppressor in different cellular 
contexts.72 Deletion of PRC2 core subunits in mouse embryos led to differentiation 
and development defects, such as gastrulation.73-75 Cancer-associated 
perturbations of PRC2 include both activating and loss-of-function mutations in 
EZH2, loss of function mutations in H3K27 demethylase genes KDM6A/B, and 
H3K27M mutations and dysregulation of the SWI/SNF chromatin remodeling 
complex, which is a PRC2 antagonist.76-78 Initially reported in Hodgkin’s 
lymphoma, the first study linking PRC2 proteins to cancer was in prostate cancer 
in 2002.79,80 It found EZH2 was overexpressed in hormone-resistant metastatic 
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prostate cancer and knockdown of EZH2 reduced cell proliferation. Many 
subsequent studies have shown that high levels of EZH2 correlated with worse 
prognosis in cancer types including breast and lung cancers, and enforced EZH2 
expression is oncogenic in the lung and drives sensitivity to pharmacological 
inhibition of EZH2.81-83  In addition to high expression of EZH2, hyperactivating 
mutation of EZH2 was first identified in follicular lymphoma.84 Gain-of-function 
mutations of EZH2 were also observed in diffuse large B-cell lymphoma, Non-
Hodgkin lymphoma and melanoma, frequently in Y646 or A682 sites of the SET 
domain.85-87 The mechanism of activating mutant EZH2 observed in various 
lymphomas might be due to its critical role in the formation of germinal center, 
which retained GC B cells in a de-differentiation state and promoted the 
lymphomagenesis.88,89 Other potential mechanisms include repression of pRB-
E2F tumor suppressing pathway, cell cycle and DNA repair-associated genes.90-92  
However, several studies have also observed loss-of-function mutations of 
PRC2 components, underlining the complex role EZH2 plays in tumorigenesis. It 
was first reported in myelodysplastic syndromes (MDS) in 2010, which showed 
that the patients harbored EZH2 chromosome 7q acquired anomalies.93,94 
Dysfunction of PRC2 core proteins have also been observed in hematopoietic 
neoplasms acute or chronic myeloid leukemia (AML/CML) and T-cell 
lymphoblastic leukemia, as well as in solid tumors including malignant peripheral 
nerve sheath tumor (MPNST).95-98 Partially deficient Polycomb activity was shown 
to accelerate the proliferation of hematopoietic stem cells.99 Although no somatic 
mutations of PRC2 subunits were observed in lung cancer, research showed that 
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deletion of the PRC2 component Eed enhanced malignancy in KRAS+/Trp53-null 
lung cancers by driving aggressive mucinous tumors and changing the tumor 
immune microenvironment, supporting a role of PRC2 as a tumor suppressor in 
lung adenocarcinomas.100 Likewise, deletion of Ezh2 in the context of oncogenic 
KRAS and intact Trp53 drove aggressive lung cancers and exacerbated immune 
cell infiltration.101 Collaborating with NF1 mutations, SUZ12 also acted as a tumor 
suppressor in melanoma, high-grade glioma, and paranasal sinus (PNS) 
cancer.95,102 Moreover, recent studies discovered a novel mutation H3K27M in 
diffuse intrinsic pontine glioma (DIPG).103,104 DIPG with H3 Lys27-to-methionine 
mutation resulted in global loss of H3K27me3, representing a newly recognized 
and aggressive subtype of cancer in the WHO classification. Removal of H3K27M 
reinstituted H3K27me2/me3 and impeded formation of murine glioma, suggesting 
the tumor suppressive role of PRC2.105 Deregulation of H3K27 demethylases 
KDM6A and KDM6B, or H3K27 acetyltransferases CREBBP and EP300 were also 
detected in bladder cancer, urothelial carcinoma, T-ALL, Hodgkin’s lymphoma and 
other cancers.106-110 
In addition to the canonical methyltransferase activity of PRC2, EZH2 
harbors non-canonical functions independent of Polycomb catalytic activity. In 
castration-resistant prostate cancer (CRPC), EZH2 exhibited a functional switch 
from methyltransferase to an activator of transcription factor androgen receptor 
(AR).111 Such a switch required phosphorylation of EZH2. In ER-negative breast 
cancer, EZH2 could transcriptionally stimulate NF-κB target gene expression 
outside of the PRC2 complex.112 JAK3-induced phosphorylation of EZH2 also 
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mediated a switch to transcriptional activator in NK/T-cell lymphoma.113 Besides, 
EZH2 could also directly methylate non-histone substrates without other PRC2 
proteins, such as GATA4, RORα, STAT3 and Talin1 proteins.114-118 In the 
scenarios above, inhibition of only PRC2 enzymatic function may not be 
mechanistically sufficient to retard tumor growth. 
Increasing evidence manifests that chromatin remodeler SWI/SNF complex 
has an antagonistic effect against PRC2 and affects its normal function in cancer.77 
Loss of SWI/SNF core subunits SMARCA4 or SMARCB1 altered H3K27 
methylation landscape due to absent PRC2 opposing by perturbed SWI/SNF 
complex and fostered an oncogenic high-methylation status in malignant rhabdoid 
tumors.119,120 Similar antagonism was also observed in epithelioid sarcoma and 
atypical chordoma. Inhibition of PRC2 has been demonstrated a synthetic lethality 
on tumors with loss-of-function mutations of SWI/SNF components in many 
cancers.121,122 Collectively, PRC2 plays divergent roles in different cellular contexts 
of cancer through distinct mechanisms, which requires comprehensive 
characterization. 
1.3 Targeted therapies in non-small cell lung cancer 
1.3.1 Non-small cell lung cancer and current therapies 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related 
death worldwide, which mainly comprises lung adenocarcinoma, squamous cell 
carcinoma and large cell carcinoma.123,124 Chemotherapy, radiotherapy, 
immunotherapy and targeted therapy provide different options to late-stage 
metastatic lung cancer patients. Although the molecular studies of NSCLC 
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identified targetable mutations of some oncogenes and tumor suppressors, no 
mutation-guided targeted therapies exist for the majority of cases.125,126 
Gain-of-function mutation of epidermal growth factor receptor (EGFR) was 
the first targetable driver mutation discovered in lung cancer, which could be 
targeted by EGFR-tyrosine kinase inhibitors (TKIs).127,128 The current druggable 
targets also include anaplastic lymphoma kinase (ALK) and ROS1 gene 
rearrangements, BRAF V600E mutations, neurotrophic receptor tyrosine kinase 
(NTRK) 1/2/3 gene fusion, KRAS mutations, MET alterations and RET 
translocations.129,130 Some other promising molecular targets are currently under 
clinical studies, including human epidermal growth factor receptor (HER-2)/ERBB2 
mutations. 
The EGFR TKIs harbor different generations of drugs with distinct 
mechanisms of action, including first-generation reversible TKIs erlotinib and 
gefitinib, second-generation irreversible inhibitors afatinib and dacomitinib, and 
third-generation mutation-selective inhibitor osimertinib.131-133 Osimertinib recently 
was approved by FDA as the first line agent, which could irreversibly bind to 
acquired EGFR T790M mutation as well as exon 21 L858R mutation and exon 19 
deletion.134,135 The first-generation ALK TKI crizotinib, which acts on both ALK and 
ROS1 translocations, was approved by FDA based on clinical trials PROFILE 
1001, 1005, 1007 and 1014.136-139 Patients resistant to crizotinib, especially with 
central neural system (CNS) metastasis due to its inability to cross blood-brain 
barrier, are recommended to use second-generation TKIs ceritinib and alectinib, 
or third-generation lorlatinib.140-143 Currently, alectinib is the preferred first-line 
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agent for ALK-positive patients, while crizotinib is still the favored option for NSCLC 
patients with ROS1 gene rearrangement.144-146 Another first-line therapy for ROS1-
positive patients is entrectinib.147 BRAF protein plays an important role in 
MAPK/ERK signaling pathway, and its most common mutation is BRAF V600E.148-
150 The first-line treatment is recommended dabrafenib combined with traiminib.151 
Vemurafenib, the first FDA-approved BRAF V600E inhibitor in melanoma, was 
currently studied in a phase 2 clinical trial for NSCLC.152-154 MET exon 14 skipping 
or amplification leads to constitutive activation of MET receptor tyrosine kinase.155 
Based on GEOMETRY NONO-1 clinical trial, capmatinib was approved by FDA 
for MET mutant or amplified NSCLC patients.156 Gain-of-function fusion mutations 
of RET enhance its signal transduction and are associated with many cancers, 
which can be targeted by FDA-approved selpercatinib or pralsetinib.157-159 
Similarly, entrectinib and larotrectinib could target fusion gene of NTRK.160 Most 
excitingly, the recent results from CodeBreaK100 study exhibited effectiveness of 
sotorasib (AMG510) in NSCLC patients with KRAS G12C mutation.161,162 KRAS 
mutation, one of the most frequent mutations in lung cancer, activates 
RAF/MEK/ERK downstream pathways and drastically promotes the tumor 
growth.163 FDA granted a priority review designation for sotorasib which sheds light 
on the potentially first agent for KRAS mutations. 
Recent advances on the targeted therapies dramatically alter the landscape 
of systemic therapeutics of lung cancer and pave the way for precision medicines 
of NSCLC patients. Future directions of targeted therapies are focused on the 
discoveries of novel molecular targets and development of new drugs or 
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combination therapies to enhance efficacy or overcome the acquired resistance to 
current treatments. 
1.3.2 EGFR in lung cancer 
EGFR/ErbB1/Her1 is the first discovered receptor tyrosine kinase in erbB 
family, which also contains ErbB2/Her2, ErbB3/Her3 and ErbB4/Her4.164,165 
Epidermal growth factor or other specific ligands binding to EGFR drives its homo- 
and/or hetero-dimerization, auto-phosphorylation of the intracellular tyrosine 
kinase (TK) domain and downstream signaling transduction, which includes 
subsequent activation of Ras/Raf/MEK/ERK, PI3K/AKT/mTOR or signal 
transducer and activator of transcription (STAT) pathways.166-168 Somatic 
mutations in the EGFR TK domain were first identified in NSCLC in 2004, which 
resulted in its ligand-independent activation.127,128 Exon 19 deletion, exon 21 
L858R point mutation and exon 20 insertion are the most common mutations of 
EGFR.169,170 EGFR is mutated in about 10-20% of lung cancer patients of 
Caucasians, while it is more frequently mutated in Asian lung cancer patients 
(around 30-50%), especially in female non-smokers.171,172 
Inhibition of the enzymatic activity of EGFR tyrosine kinase has been one 
of the most successful targeted therapies in cancer. Gefitinib, the first FDA-
approved EGFR TKI for lung cancer in 2003, competitively occupies the adenosine 
triphosphate (ATP)-binding site in TK domain and interrupts its signal 
transduction.127,128 Another first-generation reversible TKI erlotinib was then 
approved in 2004.173 Unfortunately, almost all patients developed resistance to 
TKIs eventually due to acquired secondary mutations.174,175 Substitution of 
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methionine for threonine on codon 790 (T790M) is the most common reason of 
acquired resistance, which promoted the emergence of second- and third-
generation TKIs binding to C797 in the TK domain.176-178 However, newly acquired 
resistance were observed in osimertinib-treated lung cancer patients, usually 
resulting from EGFR mutations (C797S, G724S, L718Q), loss of T790M, pathway 
bypass through KRAS, MET or PIK3CA activation or small-cell lung cancer 
transformation.179-181 Therefore, combinatorial strategies or optimizing the 
selection of patients may enhance and prolong the responses of TKIs. 
 
1.3.3 PI3K in lung cancer 
PI3K/AKT/mTOR pathway is frequently altered in diverse types of cancers, 
including NSCLC.182 PI3K, which represents the phosphoinositide 3-kinase, is an 
intracellular lipid kinase capable of phosphorylating 3’ hydroxyl groups of 
phosphatidylinositol.183,184 The PI3K family contains four classes, and PIK3CA 
gene encoding class IA PI3K p110α catalytic subunit is mutated or amplified in 
breast, liver, cervical cancer and lung cancer.185-188 The p100α subunit mutations 
most commonly occur at exon 9 E545K, followed by exon 20 H1047R and exon 
9E542K. PIK3CA E545K and E542K mutations in the helical domain unleash the 
p110α inactivation by the regulatory subunit p85, while H1047R mutation in the 
catalytic domain enhances the membrane interaction capacity of p110α.189-191 
Deregulation of Other oncogenic driver mutations including KRAS or EGFR co-
exist with PI3K aberrations and could also trigger PI3K pathway activation.192 
Phosphatase and tensin homolog (PTEN) dephosphorylates PIP3 to PIP2 and acts 
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as a negative regulator of the PI3K pathway.193-196 Reduced PTEN function by 
PTEN inactivating mutation, deletion or transcriptional suppression could also 
stimulate PI3K/AKT/mTOR pathway.197,198 Mechanistically, abnormalities of PI3K 
or PTEN lead to phosphorylated AKT by phosphoinositide-dependent kinase-1 
(PDK1), which subsequently regulates cell cycle, apoptosis and cell 
proliferation.199,200 Activated AKT also phosphorylates tuberous sclerosis complex 
1/2 (TSC1/2), which in turn stimulates mTOR and its downstream 4E-BP1 and 
S6K-1, promoting tumor growth and metabolism.201,202 
Several PI3K inhibitors have been approved by FDA, which includes 
copanlisib for relapsed follicular lymphoma, alpelisib for hormone receptor (HR)-
positive, HER2-negative, PIK3CA mutant breast cancer.203,204 Although currently 
no PI3K inhibitors are approved for lung cancer, promising preclinical studies and 
clinical trials of PI3K inhibitors as well as AKT and mTOR inhibitors are in 
progress.182 Given the modest cytotoxic effect of PI3K inhibitor alone and bypass 
through alternative upstream or downstream pathways, combination treatments 
may enhance the efficacy of PI3K inhibitors in NSCLC. 
 
1.4 Technological advances for 3-dimensional organotypic culture 
Mouse models with genetic- or carcinogen-induced transformation are used 
extensively to study autochthonous lung cancers and are considered outstanding 
preclinical models.  However, use of mice for research is costly, time-consuming 
and comes with ethical concerns. Therefore, establishing reproducible ex vivo 
models of lung cancer initiation and progression is important for the field. While 
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traditional two-dimensional (2D) cultures can be propagated successfully for some 
murine primary cancer cells in vitro, many genotypes of murine-derived tumors are 
not able to thrive in classic 2D culture scenarios. In our experience, 2D cell lines 
are very difficult to establish from murine tumors with Kras mutation 205, Egfr 
mutation 206, Kras mutation/Lkb1-loss 207 or Lkb1-loss/Pten-loss 208. Nevertheless, 
three-dimensional (3D) culture, which simulates the spatial properties of in vivo 
circumstances and has been applied to cultivate lung stem/progenitor cells 209-213, 
can be used to propagate these distinct transformed lung cells in vitro 208,214.  
 
There are various cell and tissue culture platforms for normal lung epithelial 
cells 215,216. Conventional 2D monolayer culture fails to maintain the capacity of 
long-term growth and differentiation into other lineages 217,218. 2D air-liquid 
interface (ALI) culture has been exploited to induce human bronchial epithelial cells 
(HBEC) to differentiate into mucociliary cells, albeit lack of complex tissue 
architectures 219-221. It has also been difficult to reproducibly differentiate basal cells 
in 2D-ALI culture 209. 3D-submerged culture utilized Matrigel as a substrate, which 
comprises laminin, fibronectin, collagen and other structural proteins, to 
investigate the multi-cellular differentiation and branching morphogenesis of 
epithelial stem cells 222-224. The 3D-ALI organoid culture combines the former two 
systems with specialized media aiming to sustain physiological microenvironment 
of lung epithelial cells, including the respiratory airway anatomy and hormones 
circulating in the bloodstream 211,213. In addition to normal airway organoids, this 
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technique is also employed to model cystic fibrosis, pulmonary infection and lung 
cancer 216,225.  
 
3D-ALI cultures not only provide an achievable way to model the tumors in 
vitro that could not propagate in conventional 2D cultures, but also more faithfully 
recapitulate the pathophysiological structures, function and gene expression of in 
vivo diseases. A recent study using CRISPR-based screen showed that pathways 
associated with DNA replication or other essential cellular functions were enriched 
in 2D human lung cancer lines, while cancer-specific pathways, including RAS and 
p53 pathways, were enriched in 3D spheroid culture, consistent with the belief that 
3D cultures are able to retain more characteristics of the native tissue from which 
they were derived 226. Co-culturing of tumor cells with endothelial cells, 
lymphocytes or other elements from the extracellular niche is also feasible in the 
3D organoid culture 227,228. Furthermore, the mammalian lung is a complex organ 
containing distinct stem/progenitor cell populations in various genetic and 
microenvironmental contexts, which includes basal cells and club cells in the 
proximal airways, bronchioalveolar stem cells (BASCs) and alveolar type 2 (AT2) 
cells in the distal airways. 213,229,230 To interrogate which may cells serve as cells-
of-origin for lung carcinomas, one can pre-sort differing lung cell populations and 
genetically modify these lung cells ex vivo prior to organoid seeding. This system 
also allows examination of the earliest changes during the tumorigenesis. Given 
the resemblances to in vivo, organoid cultures could exert encouraging potentials 




So far, murine tumor organoids have been employed in diverse lung cancer 
research. Several studies have used isolated ‘normal’ lung cells, genetically 
modified these cells in vitro, and subsequently demonstrated the ability of these 
populations to transplant bona fide lung cancer 214,232,233. These types of 
experiments allow for careful examination of the phenotypes associated with each 
genetic manipulation.  For example, organoid cultures were used to elucidate the 
effect of FAK inhibition on cell invasion in Lkb1-deleted lung epithelial organoid 
cultures 234. Another study discovered BCL11A as an oncogene that could drive 
squamous-like phenotypes in mouse tracheal-derived organoids 235.  Established 
lung tumors have also been used to discover new facets of disease.  3D culture 
has served as a surrogate in vitro assessment for tumor propagation efficiency of 
differing subpopulations of murine tumor cells 208,236,237.  As another surrogate 
assay to in vivo testing, effects of epigenetic inhibitors have been demonstrated 
on lung-tumor derived organoids 214,238.  Finally, murine-derived lung tumor 
organoids were also recently used to test dynamic responses to immune 
checkpoint inhibitors and MEK inhibitors 239,240.  
 
Although murine organoid cultures have recently gained popularity, there is 
currently no well-defined protocol in the literature for production of genetically 
modified murine lung organoids, which may impede dissemination and 
development of this technique. In the following studies described in this 
dissertation, we utilize a validated and detailed experimental method to establish 
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and propagate benign or malignant genetically modified lung organoids in 3D-ALI 
culture for cancer- and stem cell-related research. 
 
1.5 Goal of the projects 
The goal of the three projects described below focus on the study of 
epigenetic regulations in the tumorigenesis, progression, and therapeutic 
sensitivities to targeted therapies in non-small cell lung cancer. Cancer 
epigenetics, especially Polycomb Repressive Complex 2 (PRC2) have been 
shown deregulated in cancer research, and the inhibition of PRC2 function has 
been used in clinics. Therefore, understanding the role of epigenetic regulators in 
lung cancer and cancer stem cells is uniquely important for physicians and 






CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell lines 
Cell culture experiments were done in accordance with Institutional 
biosafety regulations. All human cell lines except HBEC3KT were maintained in 
RPMI 1640 media (Gibco, #11875-093) with 10% fetal bovine serum (VWR), 4mM 
L-glutamine (Gibco, #35050-061) and penicillin/streptomycin (Gibco) at 37°C, 5% 
CO2. A549, H460, H2030, H2009, H1975 and PC9-GR4 cells were obtained from 
the laboratory of Dr. Carla Kim at Boston Children’s Hospital, BEAS2B cells were 
a kind gift from Dr. Chengfeng Yang at University of Kentucky, and HBEC3KT cells 
241 were a kind gift from Dr. David Orren at University of Kentucky. HBECK3KT 
cells were seeded onto gelatin pre-coated plate and maintained in PneumaCult-
Ex Basal media (StemCell Tech, #05009) with PneumaCult-Ex Supplement 
(StemCell Tech, #05019), Hydrocortisone (Sigma, #H0888) and 
penicillin/streptomycin at 37°C, 5% CO2. All human lines were verified by STR 
genotyping at IDEXX laboratories at the beginning of the studies and no 
mycoplasma was detected in cultures by MycoAlert Mycoplasma Detection Kit 
(Lonza). Plasmocin (InvivoGen, #ant-mpt) was added into cultures regularly. 
Mouse primary 2D cells were obtained by plating freshly dissociated mouse tumors 
on tissue culture plates and passaging cells that adhered and grew. These cultures 
were maintained in DMEM F-12 media (Gibco, #11330-032) with 10% fetal bovine 
serum, 1% Insulin-Transferrin-Selenium (Corning, #25800CR), 4mM L-glutamine, 
penicillin/streptomycin and plasmocin at 37°C, 5% CO2. For three-dimensional 





All care and treatment of experimental animals were in accordance with 
Boston Children’s Hospital and University of Kentucky institutional animal care and 
use committee (IACUC) guidelines. For Chapter 3, cohorts of LSL:KrasG12D/+; 
Trp53flox/flox; Ezh2flox/flox (LSL: lox-stop-lox) genetically modified mouse models 
242,243 were maintained in virus-free conditions on a mixed C57BL/6x129SVj 
background. Mice were bred predominately as Ezh2fl/+ so that littermates and close 
relatives of the three Ezh2 genotypes could be analyzed for differential survival, 
metastasis, and tumor burden studies. For survival, mice that had healthy body 
characteristics at time of sacrifice were excluded from analysis. Both male and 
female mice were used for all experiments and no sex differences were noted. 
Adult mice received 2.5-2.9 x 107 PFU adeno-Cre. Mice were evaluated by 
Magnetic resonance imaging (MRI) 12 weeks after adeno-Cre infection for 
baseline scans. For Kras/Trp53/Ezh2 mouse models, JQ1 in aqueous suspension 
were made by diluting DMSO stock dropwise with + 1:1 v/v Captisol in sterile saline 
while vortexing and was i.p. injected at 50mg/kg q.d. for 2 weeks. For Nude mouse 
allograft experiment, Kras/Trp53/Ezh2 mouse tumor spheroids were dissociated 
into single cells, counted, and resuspended at 1×105 cells per 200μL of 1:1 
media/Matrigel (Corning, #356231). Female Athymic Nude Foxn1Nu/Nu mice 
(Envigo) were injected subcutaneously with 1×105 cells in 2-4 spots on flanks. 
Tumors were allowed to grow for 21 days to a mean size of 60mm3. Mice were 
then randomized into groups that received GSK-J4, JQ1 or vehicle. 100mg/kg 
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GSK-J4 or 50mg/kg JQ1 dissolved with 100% DMSO were administered by i.p. 
injection q.d. for 10 consecutive days. Tumors were measured by electronic caliper 
and tumor diameters were used to calculate tumor volumes (Tumor volume= (π x 
length x width2) / 6). For Chapter 4, the PIK3CA mouse strain was a kind gift from 
Dr. Susanne Baker at St. Jude’s (Roy, Millen, eLife 2015).  The mice were crossed 
to produce offspring with Pik3ca-E545K LSL/+;Trp53 fl/fl cohorts.244 Induction of 
medulloblastomas in Trp53-null mutant mice by somatic inactivation of Rb in the 
external granular layer cells of the cerebellum. Mice were genotyped and 
maintained in virus-free conditions with ad libitum food and water. After 6 weeks 
of age, mice were anesthetized with ketamine/xylazine and adeno-Cre (University 
of Iowa) was administered by intranasal instillation at a dosage of 2.9x106 PFU per 
mouse.  Mice were monitored for any signs of lung tumor burden, including 
hunched appearance or difficulty breathing.  Mice were sacrificed for histological 
lung analysis and to establish lung cancer organoid cultures. For xenograft assays, 
Calu3 cells were implanted subcutaneously into Nude (Foxn1Nu/Nu) mice using 
Matrigel.  Tumor growth was monitored and when tumors reached an average of 
100mm3, the mice were randomized to groups. Doses were EPZ-6438, dosed at 
250mg/kg BID in sterile water, 0.5% sodium carboxymethylcellulose, 0.1% Tween 
80 by gavage and copanlisib dosed at 14mg/kg in sterile water with 7% mannitol 
by i.p. injection every other day.245-247 Tumors were measured daily by electronic 
caliper and tumor volumes were calculated using the equation (length x width x 
width/2). For chapter 5, Cohorts of both male and female mice were used for 
autochthonous tumor experiments, and no sex differences were noted. Adult mice 
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received 2.9 x 107 PFU adeno-Cre. Immunocompromised mice (Nude, Foxn1Nu/Nu) 
were used for orthotopic intra-tracheal instillation with AdenoCre-treated 
organoids, with 6 of which being excluded due to metastatic lymphoma or cardiac 
tumor, or unexplained decease not related to tumors. 
 
2.3 Patient samples 
Patient slides were provided by the Markey Cancer Center Biospecimen 
Procurement & Translational Pathology Shared Resource Facility (BPTP SRF) of 
University of Kentucky. Discarded samples were obtained by BPTP with patient 
informed consent or waiver under an IRB approved protocol, and when transferred 
to our group, the samples had been de-identified and therefore exempt from further 
Institution Review Board approval. The tissue microarray included 83 lung 
adenocarcinomas (ADCs), 14 lung adenosquamous carcinomas (ADSCCs), 102 
lung squamous cell carcinomas (SCCs) and 13 poorly differentiated tumors 
including 1 sacromatoid tumor. For these cases, three core biopsies were removed 
from a larger tumor piece and arrayed on slides. To increase sample size, we also 
used whole tumor slides from an additional 9 ADCs, 10 ADSCCs and 2 SCCs. 
Four tumors on the TMA, one giant cell carcinoma, two large cell neuroendocrine 
and one pleomorphic carcinoma were excluded from the analysis as they did not 




2.4 Flow cytometry analysis and sorting 
Tumors were dissected from the lungs of primary mice and tumor tissue 
was chop extremely finely with surgical scissors. Tumor chunks were incubated 
with 1mL 1x PBS with 60µL Collagenase/Dispase (Sigma, #10269638001) in a 
rotator at 37oC for 30min. After washed with 1X PBS, chunks were resuspended 
in 100µL 0.25% Trypsin-EDTA (Gibco) for 2min, then neutralized with 900µL PBS 
containing 10% FBS (PF10). Next, the digested tissue was filtered through a 
100µm filter (VWR), then a 40µm filter (VWR) into a 50cc conical tube. Cell pellets 
were resuspended in 100µL Red Cell Lysis buffer (0.15 M NH4Cl, 10mM KHCO3, 
0.1 mM EDTA, in 1L distilled H2O; filtered with 0.45 µm filter and stored at RT) for 
2min at RT and added 800µL PF10. Single cell suspensions were stained using 
rat-anti-mouse antibodies including anti-mouse-EpCAM-PECy7 (BioLegend), anti-
mouse-CD31-APC (BioLegend) and anti-mouse-CD45-APC (BioLegend), anti-
NGFR (AbCAM primary, anti-rabbit-PE secondary) and anti-Sca1/Ly6A 
(BioLegend). Live cells were gated by exclusion of 4',6-diamidino-2-phenylindole 
(DAPI) positive cells (Sigma, #D9542). All antibodies were incubated for 10-15 
minutes at 1:50-1:100 dilutions for primary antibodies and 1:200 for secondary 
antibodies. Cell sorting was performed with a Sony iCyt with an 100µm nozzle. 
 
2.5 7AAD cell cell flow cytometry analysis 
Cells propagated in 2-dimensional dishes or 3-dimensional transwells were 
separated into single cells by 0.25% Trypsin. 1-10x105 cells were spun down in a 
1.5mL microtube and resuspended in cold 300µL PF10. Then the resuspended 
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cells were added dropwise to 700µL cold 70% Ethanol with slow vortexing and 
were incubated at 4°C for least 1 hour. Cells were pelleted by pulse spin and 
resuspended in 250µL/tube of 1mg/mL RNase A (Thermo Fisher, #EN0531) 
diluted in PBS for 30min. Cells were washed by 1ml PBS, pelleted and 
resuspended in 250µL/tube of 20μg/mL 7-Aminoactinomycin D (Invitrogen, 
#A1310). 30,000 events/sample were collected on the BD LSRII and analyzed with 
the ModFit LT software and results were averaged for 3 or 4 biological replicates. 
 
2.6 MRI of genetically engineered mouse model 
A Brucker ClinScan system that has 12 cm actively shielded gradients with 
maximum strength of 630 mT/m and slew rate of 6300 T/m/s was used. The tumor 
bearing mice were anesthetized by isoflurane inhalation, kept warm by a heating 
pad and imaged on the 7T system with a 2x2 array coil with a 2D gradient echoT1-
weighted sequences with parameters: 18 slices, TR = 170 ms, TE = 2.4 ms, α=38°, 
Navg=3, FOV 26 x 26 mm2, 1mm thickness, matrix size 256 x 256, for a voxel size 
of 0.102 x 0.102 x 1.0 mm. Images were gated to the animal’s respiratory cycle 
using a pneumatic respiratory monitor (SA Instruments) to remove breathing 
motion artifacts. The cardiac cycle and temperature were monitored using SA 
instruments hardware and software. The tumor burden volume and quantification 




2.7 Tumor cell 3D culture 
Mechanically and enzymatically dissociated tumor cells were resuspended 
in DMEM/F12 media containing 1x penicillin/streptomycin, 4mM L-glutamine, 10% 
fetal bovine serum, 10µg/mL Insulin (Sigma, #I-6634), 1x 
Insulin/transferrin/selenium mixture (Corning), 12.5µg/mL bovine pituitary extract 
(Invitrogen, #13028-014), 0.1µg/mL cholera toxin (Sigma, #C8052), 25 ng/mL 
mEGF (Invitrogen, #53003-018) and 25 ng/mL rmFGF2 (R+D Systems, #3139-
FB/CF), mixed 1:1 with growth factor-reduced Matrigel (Corning), and pipetted into 
a 24-well 0.4 µm Transwell insert (Corning, #CLS3470). Tumor chunks or roughly 
5,000 tumor cells were seeded into each well. MTEC/Plus (described above) 
medium (500µL) was added to the lower chamber and refreshed every other day. 
Tumor spheroids form usually in 10-14 days. To passage spheroids, media in the 
lower chamber was aspirated, 100-150uL of Dispase (Corning, #42613-33-2) was 
added over the top of well and the Matrigel was dislodged to be floating. After 
incubation at 37°C for 1-2 hours, the Matrigel was liquefied and the spheroids were 
pipetted into a tube for passage or other steps. Upon second and third passage, 
more homogeneous spheroids should arise with little residual debris remaining. 
Large and differentiated spheroids with dense squamous-like structures were 
removed. EPZ-6438 (MCE, #HY-13803), GSK-J4 (MCE, #HY-15648B) and JQ1 
(MCE, #HY-13030) were stocked as 10 mM solution in DMSO and were diluted 
according to the designated concentration into tissue culture media for use. For 
Chapter 4, BEAS2B stable cells were seeded in transwells (Corning) at a 
concentration of 2X103 cells/well in a 1:1 mixture of 10% FBS containing RPMI 
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1640 medium and phenol-red free, growth factor reduced Matrigel (Corning). A 
volume of 500 µl of RPMI 1640 medium with 10% FBS was added to the bottom 
of the plate and the culture medium was replenished every other day. The cells 
were cultured for 3 weeks and the colony growth was imaged with Cytation5.  
Organoids were quantified by counting on the images and confirmed by a blinded 
user. Five independent replicate experiments were performed, and one was 
excluded due to poor growth of the control EV cells compared to the other 
experiments. For Chapter 5, cell infections were performed as described.248 Briefly, 
sorted cells were incubated in 100µL of 6x107 pfu/mL adeno-Cre or adeno-GFP 
virus (University of Iowa) in complex media for 1-2 hours at 37°C, 5% CO2.  Cells 
were then washed by pelleting and resuspending prior to being plated in transwells 
with Matrigel and low passage neonatal lung mesenchymal support cells. The 
EGFR organoids previously maintained in transwells of 24-W plates were 
dispased, washed, digested with trypsin. Cells were seeded in 20 µl of Matrigel to 
384-well Corning Spheroid microplates at 200-300 cells/well together with 5,000 
cells/ well of mouse endothelial cells.  A 10µl of medium was applied to the top of 
Matrigel. After culturing for 3 days when there appeared noticeable organoids 
under microscope, 20 ul of drug solutions were added to the wells. After treatment 
for 3 days, cell viability was measured with CellTiter-Glo 3D (Promega). Briefly, 
25µl of GellTiter-Glo 3D lysis buffer was added to each well. After being shacked 
on a platform for 5 min and incubated at room temperature for 25min, the 
luminescence signal was measured in Cytation5 luminometer. Values were 
normalized to vehicle controls for each drug columns to yield percent survival, and 
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drug doses converted to a log scale for graphing as log(inhibitor) vs. response – 
variable slope (four parameters).  Bottoms were constrained to zero. P values 
comparing IC50 values were extracted and corrected with Holm-Sidak p value 
adjustment for each drug. 
 
2.8 Cell viability assay 
Cell lines were dissociated, counted, and plated 50µL media with 2000 cells 
(for human cells) or 5000 cells (for mouse cells) per well in 96-well plates. Edge 
wells were filled with 135 µL PBS. 50µL media with different concentrations of 
drugs EPZ-6438, GSK-J4, JQ1, carboplatin (Sigma, #C2538), etoposide, 
copanlisib, and osimertinib were added after 24 hours. After 96 hours, 50µL 
CellTiter-Glo (Promega, #G7573) was added into each well and the chemical 
luminescence was measured on a BioTek Cytation 5. Results from independent 
experiments were entered into the GraphPad Prism software to extrapolate IC50 
and p values using non-linear regression least squares fit of response vs. 
log(inhibitor) or normalized response vs. log(inhibitor). For the murine cell line 
response to GSK-J4, log(agonist) vs. response is shown as that model fit the data 
the best. For synergy assays, combinations of different doses were added into 96-
well plates as synergy matrix and measured by CellTiter-Glo. The percentage 
survival for each well compared to the control well were uploaded to 
https://synergyfinder.fimm.fi/ to calculate Bliss synergy score (readout: viability; 
baseline correction: yes) and display 3D synergy heatmap (>1 means 
synergism).249 For chapter 3, the Bliss score was calculated by the averaged 
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percentage of each dose. For chapter 4 and chapter 5, the 95% confidence interval 
of Bliss score was calculated by uploading 3 or 4 technical replicates. 
 
2.9 Soft agar transformation assay 
The soft agar transformation assay was administered following the protocol 
described in with minor modifications.250 Pre-warmed medium (DMEM + 20% FBS 
+ 1% P/S) was mixed with and the autoclaved 1.2% agarose solution (Sigma, 
#A9539) at volume ratio 1:1 thoroughly. 2 mL of the mixed solution was dispensed 
into each well of 6-well plate and wait for 1-2 hours to allow it to solidify. Cells were 
isolated, counted and 5000 cells were mixed with 1 mL of the 0.8% low melting 
agarose (Lonza, #50101) solution and 1 mL of pre-warmed medium. The mixture 
was dispensed into the 6-well plate which contained already solidified bottom layer 
of agarose. Then the plate was transferred to 4°C for 30 minutes to help 
solidification. 2mL of DMEM with 10% FBS + 1% P/S was added to each dish and 
was placed in the 37°C incubator. Images were taken after 3-4 weeks. 
 
2.10 Crystal violet growth assay 
Cell lines were dissociated, counted and 1mL media with 1000 cells per well 
was seeded into 12-well plates, 3 wells/plate in 4 plates per sample. The 4 plates 
were marked as Day 0, Day 2, Day 4, and Day 6. 6-8 hours after seeding, media 
was aspirated and cells in the Day 0 plate were fixed with 10% neutral buffered 
formalin per well for 30 minutes RT. After removal of formalin, the plates were 
washed with water 2-3 times and was let dry inverted. Same procedures were done 
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every other day on Day 2, Day 4 and Day 6 plates. After Day 6, all the 4 plates 
were stained with 400 µL crystal violet solution (1g crystal violet (0.5%, VWR 
#97061-850), 150 mL ddH20, 50 mL methanol) for at least 30 minutes. Then the 
crystal violet solution was disposed, and the plates were washed with water 3 times 
and dried inverted. The stained crystal violet was then released into solution with 
400 µL 10% glacial acetic acid (in water, Sigma #A-6283). 100 µL of the dissolved 
crystal violet was aliquoted into a 96-well plate and was read by OD595 on Cytation 
5. 
 
2.11 Quantitative RT PCR and RNA-sequencing 
RNA from treated cell lines was extracted using Absolutely RNA kits 
(Agilent) and cDNA was made using the SuperScript III kit (Invitrogen). Relative 
gene expression was assayed with Taqman probes (Thermo Fisher, #4318157) 
on the Quant Studio 3™ Real-Time PCR System (Applied Biosystems). Relative 
expression was calculated by Gene of Interest (Ctreference-Ctexprimental)-House-
keeping gene(Ctreference-Ctexperimental) and graphed on the log2 scale. House-keeping 
genes were either GAPDH/Gapdh or ACTB/Actb (B-actin) (Applied Biosystems). 
Statistics were performed on log2 data. Unless specifically indicated, the reference 
Ct value was the average of Ct values from each culture and treatment for a given 
experiment, allowing for plotting of relative mRNA levels among cultures. For RNA-
sequencing, 10,000-50,000 of freshly sorted tumors or 0.5-1 million of 2D or 3D 
cultured cells were suspended in lysis buffer for RNA extraction (Agilent columns). 
RNA was extracted by Agilent Nanoprep (3D and sorted tumors, Agilent #400753) 
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or Microprep (2D cells, Agilent #400805) kit. Library preparation and sequencing 
were sent to and performed by the University of Kentucky Oncogenomics Shared 
Resource Facility or by Beijing Genomics Institute (BGI Group). For sorted tumor 
cells, the Smart-SeqII low-input protocol was used. Sequencing reads were 
trimmed and filtered using Trimmomatic (V0.39) 251 to remove adapters and low 
quality reads. Reads from human and mouse samples were mapped to Ensembl 
GRCh38 and GRCm38 transcripts annotation (release 82), respectively, using 
RSEM 252. Gene expression data normalization and differential expression 
analysis were performed using the R package edgeR 253. Significantly 
up/downregulated genes were determined as fold change >= 2 and q-value < 0.05. 
Results were graphed by bar plots or dot plots using normalized enrichment scores 
and FDR q-value. 
 
2.12 Principal component analysis (PCA) 
For PCA, the transcripts per million (TPM) read counts of each transcript 
were log-transformed using log of TPM + 1 (using the log1p function in R for 
numerical stability), and then PCA decomposition was performed using the prcomp 
R function 254. Each sample was designated as either being from 2-dimensional 
cultures (2D) or not (other). For each principal component (PC), the sample scores 
between 2D and other were compared using ANOVA. To find transcripts with 
statistically significant loadings on a PC, each transcript’s loadings in that PC were 
tested. All other transcript’s loadings in all the other PCs were used to create a null 
distribution of loadings, and then the number of loadings greater than the tested 
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transcript’s loading value and in the same direction (positive or negative) counted, 
and divided by the number of null loadings in that direction. This fraction is the 
reported p-value for that transcripts loading in that PC. Transcript loadings values 
were considered significant if they had a p-value <= 0.05. The log-transformed 
TPM values of transcripts with significant loadings in PC3 were used to calculate 
an information-theoretically-weighted correlation, where the raw Pearson 
correlation value is weighted by the information content between the two samples 
based on their Jaccard metric, and the fraction of entries that are consistently 
present (non-zero TPM) and missing (zero TPM) between the two samples. The 
weighted-correlation was then be used as a pseudo distance (1 - correlation) for 
hierarchical clustering and ordering using the dendsort package 255. Heatmaps of 
the correlation were generated using ComplexHeatmap 256.  
 
2.13 Gene ontology enrichment 
Gene ontology (GO) enrichments of the PC3 associated genes was done 
using a custom version of categoryCompare 257. GO terms from all three of 
biological process, molecular function and cellular component were tested 
simultaneously. GO annotations to genes are based on mapping the Entrez Gene 
IDs to GO terms in the Bioconductor packages org.Mm.eg.db and GO.db version 
3.11.4. The false discovery rate correction was generated using the Benjamini-
Hochberg method. Only those GO terms with an FDR <= 0.05 and annotated to 





2.14 Gene set enrichment analysis 
For Chapter 3, GSEA was performed with GSEA version 4.0.3 (Broad 
Institute) with rank-ordered gene lists generated using all log-fold change values. 
Mouse_ENSEMBL_Gene_ID_to_Human_Orthologs_MSIGDB.v7.1.chip was 
used to map mouse genes to human orthologs. Databases queried included 
Hallmarks (h.all.v7.1), Curated (c2.all.v7.1), BioCarta (c2.cp.biocarta.v7.1), KEGG 
(c2.cp.kegg.v7.1), Reactome (c2.cp.reactome.v7.1), GO (c5.all.v7.1), Oncogenic 
Signatures (c6.all.v7.1), and Immunologic Signatures (c7.all.v7.1). Gene 
signatures that converged on common themes were selected for further analysis 
and graphing of enrichment scores and FDRs for specific contrasts. For Chapter 
5, gene set enrichment analysis was performed with GSEA version 4.1.0 with gene 
expression vsd-normalized by DESeq2 R package. Mouse genes were mapped to 
human orthologs by Mouse-
ENSEMBL_Gene_ID_to_Human_Orthologs_MSIGDB.v7.4 chip and queried for 
Hallmarks (h.all.v7.4) and Oncogenic signatures (c6.all.v7.4). Results were 
graphed by bar plots using normalized enrichment scores and FDR q-values 
(q<0.05 as significant difference). 
 
2.15 Chromatin Immunoprecipitation and qPCR (ChIP-qPCR) 
Tumor cells were resuspended in Buffer A from Covaris kit (Covaris, 
#520154). Then cells were cross-linked with 11.1% formaldehyde for 5 min at RT, 
quenched by Quenching buffer E, washed in cold PBS and pulse spun. Pellets 
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were re-suspended in Lysis buffer B and rotated for 10min at 4ºC. Lysed nuclei 
were washed with Wash buffer C, resuspended in Sonication buffer D3 and 
sonicated with the Covaris M220 Focused-ultrasonicator to obtain chromatin 
fragment lengths of 200-to-1500bp judged by a Bioanalyzer DNA High sensitivity 
kit (Agilent #5067-4626). Fragmented chromatin was diluted in Sonication buffer 
D3 and incubated overnight at 4ºC with FOXP2 (Sigma, #HPA000382), H3K27ac 
(Abcam, #ab4729) or H3K27me3 (Millipore, #07-449) antibodies. Then 40µL 
Protein A/G 1:1 mixed magnetic Dynabeads (Invitrogen) were added and rotated 
at 4ºC for 2 hours. Immunoprecipitates were washed with cold ChIP buffer (1% 
Triton X-100, 0.1% Deoxycholate, 50mM Tris-HCl pH 8.1, 150mM NaCl, 5mM 
EDTA), High salt buffer (1% Triton X-100, 0.1% Deoxycholate, 50mM Tris-HCl pH 
8.1, 500mM NaCl, 5mM EDTA), LiCl buffer (250mM LiCl, 0.5% IGEPAL, 0.5% 
Deoxycholate, 10mM Tris-HCl pH 8.1, 1mM EDTA) and TE buffer (10 mM Tris-
HCl and 1 mM EDTA). Immunoprecipitated (or no IP input) DNA was incubated 
with 50µL Elution buffer (1% SDS and 0.1M NaHCO3) in 55ºC water bath 
overnight. The eluted DNA was treated with RNase A and Proteinase K, and 
column purified with DNA clean and concentrator kit (Zymo Research, #D4014). 
ChIP-qPCR was run with the Power SYBR reagents (Thermo Fisher, #100029284) 
on the Quant Studio 3™ Real-Time PCR System for the mouse Foxp2/human 
FOXP2 TSS, ATG and enhancer regions and mouse Gapdh/human GAPDH (3 
biological or technical replicates). The Foxp2/FOXP2 ChIP-qPCR data were 
normalized to Gapdh/GAPDH abundance by a delta(deltaCt) method to control for 




2.16 Western blotting 
Whole cell extracts were made in RIPA buffer (0.5% Deoxycholate, 1% 
IGEPAL-CA630, 0.1% sodium dodecyl sulfate, 150mM NaCl, 50mM Tris-8.1), 
lysates were cleared by centrifugation, and protein concentrations were quantified 
with the Pierce BCA Protein Assay Kit (Thermo Fisher, #23225). For Western 
blotting, 1-60µg of protein extract per sample was denatured with heat and 
reducing agents, separated on a 4-15% acrylamide gel (BioRad) and transferred 
to nitrocellulose membranes (GE Healthcare, #10600002). Antibodies used for 
Western blotting were: EZH2 (Cell Signaling, #5246s, 1:1000), SUZ12 (Active 
Motif, #39357, 1:1000), EED (Millipore, 09-774, 1:500), Histone H3 (Abcam, 
#ab1791, 1:5000), H3K27me3 (Cell Signaling, #9733s, 1:1000), FOXP2 (Sigma 
#HPA000382 1:1000 for human sample, Abcam #ab16046 1:1000 for murine 
sample), phospho-AKT (Cell Signaling, Cat#4060s, 1:2500), AKT (Cell Signaling, 
Cat#4691s, 1:2500) all incubated overnight at 4ºC. Histone H3 was used as 
loading control. All antibodies have detailed species validation available online 
from vendors. Secondary anti-rabbit IgG, HRP-linked antibody (Novus #NB7160, 
1:10000) was incubated for 1 hour at room temperature. After washing, 
chemiluminescence was visualized with West Pico PLUS Chemiluminescent 




2.17 Histology and immunohistochemistry 
Mice were anesthetized, hearts were removed and the lung lobes were 
inflated with neutral-buffered 10% formalin and fixed overnight at room 
temperature, and then transferred to 70% ethanol, embedded in paraffin and 
sectioned at 4-5 μm. Hematoxylin and eosin stains, Alcian Blue and Masson’s 
Trichrome stains were performed in the Biospecimen Procurement & Translational 
Pathology Shared Resource Facility (BPTP SRF) of the University of Kentucky 
Markey Cancer Center or at Harvard Medical Center. For tumor burden analysis, 
H&E stained slides were scanned with an Epson scanner and 2800-3200 dpi 
resolution 48-bit color. Images were cropped, white space was masked, and 
trachea/esophagus/lymph nodes were masked. Images were auto-contrasted and 
saved as 16-Bit grayscale, then opened in ImageJ software. Threshold settings 
were first set to cover all of the lung and measurements were taken, 0.0001-infinity. 
Then auto threshold was set and modified if needed to exclude areas that were 
heavily infiltrated with immune cells but not tumor and to exclude thickened 
bronchi, and measurements were taken, 0.0001-infinity. The ratio of tumor to lung 
was calculated for each mouse. For some mice, a representative lobe or residual 
lung with many tumors intact or partially intact were used so that tumors could be 
harvested for other analyses. Nuclear grade was determined by Dr. Roderick 
Bronson at Harvard Medical School on a set of histology slides representing 
tumors harvested 108 days or more past adeno-Cre. Descriptions for nuclear 
grade criteria were previously published 242. Grade 5 criteria were not used. Grade 
4 included the criteria listed in the original paper and the appearance of tumor cells 
38 
 
invading into normal tissue or into blood vessels. Immunohistochemistry was 
performed with either Tris or Citrate buffer antigen retrieval in the Brainson 
Laboratory or the BPTP SRF, and staining was visualized with brown DAB 
substrate and counterstain was either Mayer’s or Harris’s hematoxylin. Slides were 
batch stained to reduce variability. Scoring of H3K27me3, EZH2 and FOXP2 
nuclear staining was performed with Nikon NIS-Elements AR software on 20x 
images obtained in a blinded fashion. Regions of stroma (blood cells, vessels, 
fibroblasts and connective tissue) were deleted from the images by hand in 
Photoshop. Edited images containing predominately tumor nuclei were analyzed 
using Nikon’s dark spot detection module on the blue channel at eight different 
equally spaced intensity cutoffs, which represent increasing stringency for positive 
IHC stain. Nuclei counted at intensities 4-8 were considered positive, while nuclei 
counted at intensity 1 represented all nuclei for a given image. Percentage of 
positive nuclei in bins 4-8 were calculated. For binning tumor samples in Figures 
7d and 7e tumors with greater than 20% positive nuclei were considered ‘high’ for 
EZH2 and tumors with greater than 40% positive nuclei were considered ‘high’ for 
H3K27me3. Imaging was performed on a Nikon Ti-Eclipse inverted microscope. 
Immunofluorescence staining were done as described previously 258. The slides of 
tumors or organoids were immunostained with primary antibodies for CCSP, pro-
SPC, Acetylated-tubulin, P63, SOX2, KRT5, MUC5ac and secondary antibodies 
donkey anti-mouse/goat Alexa 488 (FITC), anti-mouse/rabbit/goat Alexa 594 
(TRITC), anti-rabbit/goat Alexa 647 (Cy5), and mounted with ProLong Gold 
Mounting media with DAPI. Fluorescence images were captured on Nikon Ti-
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Eclipse inverted microscope. Exposures and look-up-tables were matched for all 
images of each stain at each magnification, with the exception of DAPI look-up-
tables that were set for best visualization. 
 
2.18 Transwell cell migration assay 
Migration assays were performed with 24-well transwell plates with 8.0µm 
Pore (Corning, #CLS3422). Briefly, cells were typsinized into single cells by 0.25% 
Trypsin-EDTA and counted. Then 1-5x105 cells in 100μl serum-free culture media 
was added into the top chamber insert and incubate for 10min. The bottom 
chamber was filled with 600μl media containing 10% FBS. After 24-hour 
incubation, nonmigratory cells were removed with a cotton swab, and the migratory 
cells were fixed with formalin for 10min, 70% Ethanol for 10min, stained with 0.2% 
crystal violet for 10min and washed off with tap water. Ten 20x images of each 
transwell were taken on BioTek Cytation 5, the numbers of crystal violet stained 




The pLKO.1 EZH2 shRNA (TRCN0000040076 and TRCN0000040073) and 
FOXP2 shRNA (TRCN0000426742, TRCN0000426178) construct clones were 
purchased from SIGMA and the shGFP plasmid 12273 and pENTR-FOXP2 
plasmid 47053 were available on Addgene 259. The FOXP2 over-expression 
construct was flipped into pLenti6.3/V5-DEST vector (Invitrogen). For BEAS-KP 
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cell generation, KRASG12V and p53R175H lentiviruses were used 260. KRASG12V 
was a kind gift from Aveo Pharmaceuticals and p53R175H was a kind gift from the 
Kuperwasser laboratory at Tufts Medical Center. Lentivirus was packaged in 
HEK293T cells with above vectors together with the packaging construct pCMV 
DR8.2Dvpr and VSV-G-pseudotyped lentiviral vectors by FuGENE 6 (Promega, 
#E2691), using established protocols 261. Cell lines were infected with viral-
containing supernatant for a period of 4-8 hours. Infected cultures were selected 
with puromycin (hairpins) or blasticidin (FOXP2 and p53R175H) 5 days post 
infection. For BEAS2B cells in Chapter 4, KRASG12V and p53R175H lentiviruses 
and PIK3CA retroviurses were used.  KRAS-G12V was a kind gift from Aveo 
Pharmaceuticals and p53-R175H was a kind gift from the Kuperwasser laboratory 
at Tufts Medical Center.262  PIK3CA vectors were purchased from Addgene.263 
Infected cultures were selected by puromycin (PIK3CA vectors), GFP-sorting 
(KRAS-G12V) or blasticidin (p53-R175H).  PCR for viral inserts was performed on 
isolated genomic DNA using a 59°C annealing temperature with the following 
primers:  
PIK3CA F:  5' – CCATACGACGTGCCAGATTA – 3',  
              R: 5' – CCTCACGGAGGCATTCTAAA – 3',  
P53 F:  5' – CCTCACGGAGGCATTCTAAA – 3',  
       R: 5' - GCTCGACGCTAGGATCTGAC - 3',  
KRAS F:  5' - TAGAGGATCCACTAGTACCACCATG - 3',  




2.20 Statistics and reproducibility 
All graphed data were presented as mean ± standard error of the mean 
(s.e.m.) unless otherwise noted. In boxplots, the center line shows the median 
values while the bounds correspond to the first and third quartiles, and upper and 
lower whiskers extend to the highest and lowest values, respectively. For mouse 
experiments, the biological n represented individual donor mice, and often several 
replicate experiments for each donor mouse were averaged to produce the 
biological replicates. For human cell line experiments with the exception of 
validation of FOXP2 over-expression by RT-qPCR (Supplementary Fig. 6a), at 
least three independent replicate experiments were used to generate averaged 
data. Unless indicated, p values represent 2-tailed Student’s t-test with equal 
variance that were used to compare continuous outcomes between two 
experimental groups. Where indicated, ANOVA with pairwise comparisons were 
used for comparing multiple groups. ANOVA with repeated measures was used to 
compare the tumor change at each time point in the tumor growth studies. Fisher’s 
exact tests were used to compare binary outcomes between groups. Kaplan-Meier 
curves and Mantel Cox log-rank tests were used for survival outcomes. Pearson’s 
correlation coefficients were used to quantify correlations of marker expressions. 
A p-value less than 0.05 was considered statistically significant. * represents p-
value <0.05, ** p-value <0.01 and *** p-value <0.001. Adjusted p-values are shown 
for figure 5.12. Statistical analyses were carried out using Excel, GraphPad Prism 
or SAS version 9.4. The RNA-sequencing data generated for Chapter 3 are 
available at NCBI GEO database under accession number: GSE154689. Five 
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sorted samples of varied genotypes were excluded due to questions about sorter 







CHAPTER 3. POLYCOMB DEFICIENCY DRIVES A FOXP2-HIGH AGGRESSIVE 
STATE TARGETABLE BY EPIGENETIC INHIBITORS 
3.1 Brief introduction 
Lung cancer is the leading cause of cancer-related death worldwide264. 
More than 85% of cases are classified as non-small cell lung cancer (NSCLC), 
among which adenocarcinoma (ADC), arising from distal lung epithelium, is the 
dominant type265. While some advances have been made with targeted therapies 
to driver mutations including KRASG12C, mutant EGFR and mutant ALK, a large 
percentage of lung adenocarcinomas remain for which chemotherapy is the first 
line of treatment165,266. Given the importance of chromatin biology in cancer, it 
stands to reason that epigenetic inhibitors may offer an avenue to drive therapeutic 
vulnerabilities for many cancer types, including lung adenocarcinomas267.  
Enhancer of zeste homolog 2 (EZH2), the functional enzymatic component 
of the Polycomb Repressive Complex 2 (PRC2), is best known as a histone 
methyltransferase that tri-methylates histone H3 at lysine 27 (designated as 
H3K27me3) to silence chromatin regions268. PRC2 plays a key role in embryonic 
development and maintenance of cell identity and may act as an oncogene or 
tumor suppressor in different cellular contexts78. Cancer-associated perturbations 
of PRC2 include both activating and loss-of-function mutations in EZH2, loss of 
function mutations in H3K27 demethylase genes KDM6A/B, and H3K27M 
mutations and dysregulation of the SWI/SNF chromatin remodeling complex, 
which is a PRC2 antagonist77,78. Many studies have shown that high levels of EZH2 
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correlated with worse prognosis in cancer types including breast and lung 
cancers82,83, and enforced EZH2 expression is oncogenic in the lung and drives 
sensitivity to pharmacological inhibition of EZH281. However, several studies have 
observed a de-coupling of EZH2 protein levels from H3K27me3 levels214,269-271, 
and EZH2 is known to have non-catalytic functions115,272,273, underlining the 
complex role EZH2 plays in tumorigenesis. Supporting a role of PRC2 as a tumor 
suppressor in lung adenocarcinomas, deletion of the PRC2 component Eed 
enhanced malignancy in KRAS+/Trp53-null lung cancers by driving aggressive 
mucinous tumors and changing the tumor immune microenvironment100. Likewise, 
deletion of Ezh2 in the context of oncogenic KRAS and intact Trp53 drove 
aggressive lung cancers and exacerbated immune cell infiltration101. Collectively, 
EZH2 plays divergent roles in different cellular contexts of cancer, which requires 
comprehensive characterization.  
Discovery of the contexts in which pharmacological inhibitors of epigenetic 
enzymes, including EZH2, can be combined for the best anti-cancer outcomes is 
an important challenge for the field. Recently tazemetostat (EPZ-6438), an inhibitor 
of the catalytic activity of EZH2, was approved for treatment of advanced 
epithelioid sarcoma, and numerous clinical and preclinical trials are focused on 
combining EZH2 inhibitors with other drugs. One clear consequence of EZH2 
inhibition is a dramatic shift in the immune cell microenvironment, which many are 
hoping to further exploit274,275. In addition, a PRC2-low state that can be achieved 
through EZH2 inhibition may sensitize tumor cells to additional epigenetic 
therapies. For example, due to a switch from H3K27me3 to acetylation at the same 
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residue, PRC2-deficient malignant peripheral nerve sheath tumors were found to 
be sensitive to an inhibitor of H3K27ac-reader bromodomain and extra-terminal 
motif (BET) proteins when combined with MEK inhibition276. Similarly, JQ1, the 
BET inhibitor, showed combinatorial synergy with EZH2 inhibition in diffuse 
intrinsic pontine glioma, which is already sensitive to EZH2 inhibitors due to altered 
epigenetic state caused by H3K27M mutations104,277,278. Lastly, GSK-J4, which 
inhibits histone demethylases and stabilizes H3K27me3, has been shown effective 
at defeating chemo-resistant lung cancer cells and mammosphere-derived breast 
cancer stem cells, both of which harbored decreased H3K27me3279-281. Therefore, 
identifying proper contexts or combinatorial regimens is critical to realize the full 
potential of epigenetic inhibitors for cancer therapy. 
In addition to gene expression control through epigenetic mechanisms, 
transcription factors are known to be master regulators of important cellular 
phenotypes including stemness, proliferation, and migration282,283. Forkhead box 
protein P2 (FOXP2) is a member of the FOX transcription factor family that all 
share a conserved forkhead or “winged-helix” DNA binding domain284. In addition 
to its role in the development of speech, FOXP2 is also known to be expressed in 
developing embryonic lung and can be used to mark induced pluripotent stem cell 
derived alveolar lung progenitors285,286. Knockout of Foxp2 led to severely 
defective postnatal lung alveolarization in murine models287. In the adult, FOXP2 
was found expressed in the distal lung epithelium, and can directly inhibit lung cell 
differentiation genes including surfactant protein C and secretoglobin family 1A 
member 1 transcription288,289. In cancers, FOXP2 activity has been identified as 
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dysregulated 290. While FOXP2 repression is correlated with poor outcome in 
breast cancers, increased expression is associated with relapse in prostate cancer 
and lymphoma291-294. Despite clues suggesting the importance of this transcription 
factor in maintaining stemness in lung epithelium, the roles of FOXP2 in lung 
adenocarcinoma have yet to be explored.  
In this study, we demonstrate that Ezh2 haplo- and full-insufficiency lead to 
divergent phenotypes in KRAS+/Trp53-null lung ADC by using genetically 
engineered mouse models (GEMMs). Pharmacological inhibition of BET proteins 
or H3K27 demethylases impeded tumor growth preferentially in PRC2-deficient 
lung tumors in vitro and in vivo. Biochemical and transcriptional analysis revealed 
PRC2 ablation-induced FOXP2 enrichment promotes lung tumor stemness and 
migratory potency, partially phenocopying the effect of Ezh2 knockout in GEMMs. 
Moreover, FOXP2 could be attenuated by BET inhibitor JQ1. Taken together, 
FOXP2 expression governed by Polycomb activity dictates the tumor 
aggressiveness and responsiveness to epigenetic therapies in lung cancer. 
 
3.2 Ezh2 haplo- and full-Insufficiency drive distinct phenotypes in 
KRAS+/Trp53-null lung cancer 
To address the role of EZH2 in lung tumor initiation and progression, we 
generated the LSL:KrasG12D/+; Trp53flox/flox (LSL: lox-stop-lox) genetically 
engineered mouse model with either zero, one, or two floxed alleles of Ezh2 and 
induced autochthonous lung tumors by intranasal adeno-Cre (AdCre) virus 
administration (Fig. 3.1a). We analyzed closely related mice of each Ezh2 
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genotype at a variety of timepoints by histological examination of the resulting 
KRAS+/Trp53-null lung tumors (Fig. 3.1b). Mice with one floxed allele of Ezh2 
(Ezh2 heterozygous) had lower tumor burden (30%) when compared with Ezh2 
wild-type mice (37%) between 82 and 130 days after AdCre delivery (Fig. 3.1c 
and 3.1d). Ezh2 heterozygous mice also had tumors with lower nuclear grade and 
showed increased survival (131.5-day median) when compared with Ezh2 wild-
type mice (121.5-day median) (Fig. 3.2a and 3.2b). These results were consistent 
with the role of EZH2 as an oncogene 81,100. However, mice with two floxed alleles 
of Ezh2 (Ezh2 null) had significantly higher tumor burden (47%), significantly 
higher nuclear grade, and a significantly shorter survival (114.5-day median) when 
compared to Ezh2 heterozygous tumors. Strikingly, Ezh2 null tumors had a 
significantly higher propensity to metastasize to areas including lymph nodes, 
pleural space, chest wall, diaphragm, and liver than Ezh2 wild-type or 
heterozygous tumors (Fig. 3.2c). Immunohistochemical staining revealed that 
Ezh2 null tumor cells were nearly uniform in the lack of EZH2 expression and had 
heterogenous but overall low staining for H3K27me3 (Fig. 3.2d and 3.2e). Rare 
lung tumors and one lymph node metastasis were noted to retain EZH2 expression 
in the Ezh2fl/fl mice, and EZH2 expression was heterogenous in Ezh2 wild-type and 
heterozygous mouse tumors. H3K27me3 staining was uniformly moderate in both 
Ezh2 wild-type and Ezh2 heterozygous tumors, appearing to be most prominent in 
well differentiated Ezh2 heterozygous tumors. Notably, for Ezh2 null tumors, 
despite heterogeneity among nodules, areas with larger pleomorphic nuclei had 
low H3K27me3 staining. Due to the previous reports that loss of Eed in the 
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KRAS+/Trp53-null model drove epithelial to mesenchymal transition (EMT) and 
mucinous adenocarcinomas100, Alcian Blue and Masson’s Trichrome stains were 
performed. Rare areas of intracellular Alcian Blue staining were observed in Ezh2 
null tumors, and a few cases of goblet cell and squamous differentiation were 
observed in Ezh2 heterozygous tumors, although the majority of the tumors in all 
Ezh2 genotypes had no Alcian Blue stain (Fig. 3.2f). Consistent with a more 
aggressive phenotype, some Ezh2 null tumors, especially the more poorly 
differentiated tumors, had green collagen staining. Collectively, these data suggest 
that full and partial insufficiency for Ezh2 drive distinct phenotypic outcomes in 
KRAS+/Trp53-null lung adenocarcinomas with full insufficiency driving more 














Figure 3. 1 Ezh2 haplo- and full-Insufficiency drive distinct tumor burdens in 
KRAS+/Trp53-null lung cancer 
 
(a) Schematic for LoxP-mediated deletion of Ezh2 to generate EZH2 wild-type, 
heterozygous, and homozygous null KRAS/Trp53-null GEMMs. (b) 
Representative H&E stained cross sections from lungs of closely related mice that 
were induced and sacrificed at the same timepoint show an Ezh2 null mouse that 
has higher tumor burden than its matched Ezh2 WT or heterozygous cohort. (c) 
Tumor burden as percentage of total lung was analyzed by ImageJ for indicated 
mice at days 82-130 post tumor induction, n=34 Ezh2 WT, n=44 Ezh2 
heterozygous and n=30 Ezh2 null, * indicates p=0.0287 Ezh2 WT vs Ezh2 






pairwise comparisons. (d) Tumor burden relative to the whole lung indicated at the 
different time points post Adeno-Cre, *  at Day116-130 indicates p=0.027 Ezh2 WT 
vs null, *  at Day91-105 indicates p=0.026 Ezh2 heterozygous vs null, ** indicates 










































Figure 3. 2 Ezh2 haplo- and full-Insufficiency drive distinct phenotypes in 
KRAS+/Trp53-null lung cancer 
 
(a) Overall survival of mice of indicated genotypes is graphed, n=10 Ezh2 WT, 
n=18 Ezh2 heterozygous and n=18 Ezh2 null, * indicates p=0.022 Ezh2 WT vs 






Mantel-Cox log-rank test. (b) Nuclear grade was scored by a blinded pathologist 
as done previously 242 on sections 108-120 post tumor induction, n=6 Ezh2 WT, 
n=9 Ezh2 heterozygous and n=8 Ezh2 null, * indicates p<0.041 by ANOVA with 
pairwise comparisons. (c) Mice of indicated genotypes were scored as having 
metastasis or not by gross examination and histology at days 91-130 post tumor 
induction, n=30 Ezh2 WT, n=36 Ezh2 heterozygous and n=25 Ezh2 null, * 
indicates p=0.012 and *** indicates p=0.0008 by Fisher’s Exact test. (d) 
Representative images of tumor sections with the indicated stains, scale 
bar=100µm. (e) Box and Whisker plot of average percentage of positively stained 
tumor nuclei for EZH2 in mouse lung tumors with the indicated Ezh2 genotypes, 
*** indicates p<0.001 compared with Ezh2 null. (f) Representative images of Alcian 
Blue and Masson’s Trichrome stains on the mouse tumor sections with the 
indicated genotypes, scale bar = 100µm.  
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3.3 Model systems differ in cell cycle and gene expression 
Next, we sought to understand the major mechanisms behind the different 
phenotypes among the three genotypes. To this end, we used four different cell 
states to study: 2D cell lines, 3D tumor spheroids, freshly sorted tumor cells or 
total (bulk) tumors. The sorted cells are almost pure epithelial tumor cells without 
endothelial cells, lymphocytes and other blood cells from the microenvironmental 
niche, which were retained in the total tumor samples. In general, 3D tumor 
spheroids had cellular structures reminiscent of those found in tumors, including 
pseudo stratification and apical-basal polarity of the epithelial cell layers (Fig. 
3.3a). Consistent with previous reports100, 2D Ezh2 null cells exhibited more 
elongated mesenchymal-like cells than 2D Ezh2 wild-type cells, whereas in cross-
sections of 3D tumor spheroids and in vivo tumors, the mesenchymal-like 
phenotype was less obvious. We next queried Ezh2 mRNA expression patterns, 
and found that in both 2D and 3D states, Ezh2 null cells expressed lower level of 
Ezh2 than the other two genotypes (Fig. 3.3b). The expression of PRC2 
associated proteins was verified in immunoblot, in which Ezh2 null cells showed 
lower EZH2 and H3K27me3 levels compared with Ezh2 wild-type or heterozygous 
lines (Fig. 3.3c). EED and SUZ12, the other two primary PRC2 components, were 
also partially degraded in Ezh2 null cultures, presumably due to the complex 
disassembly of PRC2-EZH2295,296. Interestingly, 2D cultures expressed more 
EZH2 than 3D cultures by mRNA analysis, suggesting that 2D cell culture drives 
an artificial increase in EZH2 expression.  
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Because cellular proliferation is one of the key aspects of any culture 
system, we next compared the cell cycle profiles of 2D cell lines and 3D tumor 
spheroids. Cell cycle profiles of 2D cells and 3D spheroids were dramatically 
different, with 2D cells showing much higher percentages of cells in S phase and 
much lower percentages of cells in G0/G1 phase than 3D tumor spheroids for 
every Ezh2 genotype (Fig. 3.4a and 3.4b), which coincides with the observations 
that 2D cells propagate much faster than 3D spheroids. Intriguingly, mono-allelic 
deletion of Ezh2 resulted in G2/M arrest in 2D cells, but led to G0/G1 arrest in 3D 
tumor spheroids. In contrast, biallelic loss of Ezh2 did not trigger the arrest of 2D 
cells in G2/M or 3D tumor spheroids in G0/G1, partially explaining opposing 
phenotypes driven by Ezh2 heterozygous and homozygous deletion. However, 
Ezh2 biallelic deletion in 3D tumor spheroids induced more S and G2/M phases 
and less G0/G1 phase compared with mono-allelic deletion, demonstrating that 
the cell cycle regulation is one mechanistic difference between these Ezh2 
genotypes observed only in 3D cultures. 
To understand the transcriptional differences that may contribute to the 
disparity of phenotypes in the different systems, we compared mRNA from the 
four models (independent of Ezh2 genotype) by RNA-sequencing. Unsupervised 
hierarchical clustering of samples using distances derived from weighted 
correlation showed that in vivo sorted tumors form their own cluster that is distinct 
from all other samples, while total tumor is also distinct from the 3D tumor 
spheroids and 2D cells, regardless of Ezh2 phenotype (Fig. 3.5a). Principal 
Component (PC) analysis performed on all samples determined that PC3 showed 
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a stratification of the 2D samples away from the other three groups (Fig. 3.5b). 
This PC is enriched for genes associated with epithelial cell proliferation, lung 
development, wound healing, cell-cell interactions and immune response (Table 
3.1). Similarly, Gene Set Enrichment Analysis (GSEA) showed that compared with 
2D cells, 3D tumor spheroids and in vivo sorted tumors had enrichment of 
transcriptional signatures related to immunity and lung lineage determination (Fig. 
3.5c and Table 3.2). In contrast, 2D cells were enriched for cell cycle gene 
signatures, consistent with our findings in 2D cultures of increased S phase in the 
cell cycle analyses. Notably, although some chromatin-related signatures showed 
discordance of enrichment patterns, genes identified as changed by EZH2 and 
EED knock-down in fibroblasts were similarly enriched in 3D tumor spheroids and 
in vivo tumors when each was compared to 2D cultures297. Similarly, a recent 
study using CRISPR-based screen showed that pathways associated with DNA 
replication or other essential cellular functions were enriched in 2D human lung 
cancer lines, while cancer-specific pathways, including RAS and p53 pathways, 
were enriched in 3D spheroid culture226. Consistent with the cell cycle analysis, 
Ezh2 heterozygous deletion resulted in significantly enriched hallmarks 
associated with G2/M checkpoints and E2F targets only in 2D culture (Fig. 3.5d). 
There was no such enrichment induced by Ezh2 full deletion in 2D culture, but it 
led to reduced transcriptional enrichment in G2/M checkpoints and E2/F target 
genes in sorted tumors compared to Ezh2 wild-type (data not shown). These data 
demonstrate the substantial differences among culture systems in growth patterns 
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and transcriptional states, and suggest adopting appropriate models for the study 


























Figure 3. 3 Model systems differ in morphology and expression of PRC2 
molecules 
 
(a) Representative images of in vivo tumor histology, in vitro 3D tumor spheroid 
histology and 2D cell cultures of the indicated Ezh2 genotypes, scale bar=100µm. 
(b) Expression of Ezh2 mRNA in mouse primary 2D cells and 3D tumor spheroids 
of the indicated Ezh2 genotypes determined by RT-qPCR, n=3 different cultures 
for each genotype, * indicates p<0.043, ** indicates p<0.009. (c) 2D and 3D cells 
were examined for expression of the indicated proteins by immunoblot. H3 









Figure 3. 4 Model systems differ in cell cycle 
 
(a) Percentages of cells in each cell cycle phase were measured by 7AAD cell 
cycle flow cytometry 2D cells and 3D tumor spheroids of the indicated Ezh2 
genotypes, n=4 Ezh2 WT, n=3 Ezh2 heterozygous and n=4 Ezh2 null for 2D and 
n=3 Ezh2 WT, n=4 Ezh2 heterozygous and n=3 Ezh2 null for 3D, * indicates 
p<0.039, ** indicates p<0.009, *** indicates p<0.001. (b) Cell cycle profiles of 2D 
vs 3D cells within the indicated genotypes, * indicates p<0.039, ** indicates 







Figure 3. 5 Model systems differ in gene expression 
 
(a) Heatmap of sample-to-sample correlations using highest loading genes from 
PC3, where the Pearson correlations are weighted by sample-sample information 
and sample-sample consistency (see Methods). The 1 - correlation value was then 
used as a pseudo distance for hierarchical clustering and ordered using default 
argument of dendsort, n=17 for total tumor, n=13 for sorted tumor, n=20 for 2D 
cells and n=21 for 3D spheroids. (b) Principal component analysis of the variability 





PC2 (left graph) and PC1 and PC3 (right graph) of a principal component 
decomposition of the log(TPM + 1) values for each sample are shown. (c) Rank 
ordered gene lists were queried against the MSigDB databases and enrichment 
scores of selected gene signatures enriched in 2D, 3D, or in vivo sorted tumors 
were plotted. Size of dots estimates false discovery rate (FDR). (d) GSEA plots 
evaluating the changes in the indicated gene signatures in 2D Ezh2 heterozygous 




































GO:0031012 extracellular matrix 1.60E-14 2.703872 41.16202 94 5.87E-12 
GO:0045177 apical part of cell 7.09E-14 2.780568 36.31424 85 2.31E-11 
GO:0062023 collagen-containing extracellular matrix 1.81E-13 2.916182 31.20204 76 5.73E-11 
GO:0009611 response to wounding 4.18E-12 2.523357 39.66362 86 1.13E-09 
GO:0048871 multicellular organismal homeostasis 6.13E-12 2.457509 41.95529 89 1.60E-09 
GO:0009615 response to virus 1.19E-11 3.080934 23.09304 59 3.02E-09 
GO:0030198 extracellular matrix organization 1.22E-11 3.044034 23.71003 60 3.05E-09 
GO:0043062 extracellular structure organization 1.44E-11 3.029359 23.79817 60 3.48E-09 
GO:0016324 apical plasma membrane 1.92E-11 2.825989 27.67639 66 4.54E-09 
GO:0050900 leukocyte migration 4.28E-11 2.715119 29.43922 68 9.71E-09 
GO:0050673 epithelial cell proliferation 4.95E-11 2.489046 36.75495 79 1.10E-08 
GO:0030595 leukocyte chemotaxis 1.03E-10 3.275724 18.24526 49 2.11E-08 
GO:0051607 defense response to virus 1.63E-10 3.133232 19.65552 51 3.28E-08 
GO:0060326 cell chemotaxis 2.30E-10 2.787231 25.38471 60 4.45E-08 
GO:0050839 cell adhesion molecule binding 2.40E-10 3.012289 21.06579 53 4.58E-08 
GO:0030546 signaling receptor activator activity 2.61E-10 2.304516 42.13157 85 4.93E-08 
GO:0048018 receptor ligand activity 3.20E-10 2.305973 41.60273 84 5.99E-08 
GO:0042060 wound healing 4.67E-10 2.54032 31.02576 68 8.53E-08 
GO:0031589 cell-substrate adhesion 5.28E-10 2.572974 29.79178 66 9.49E-08 
GO:0042379 chemokine receptor binding 6.14E-10 6.770754 4.935917 22 1.10E-07 
GO:0001667 ameboidal-type cell migration 6.99E-10 2.403898 35.34469 74 1.24E-07 
GO:0016323 basolateral plasma membrane 8.40E-10 2.999406 19.91995 50 1.47E-07 
GO:0043588 skin development 2.12E-09 2.678616 24.85587 57 3.55E-07 
GO:0046977 TAP binding 2.90E-09 93.61202 0.881414 9 4.83E-07 
GO:0050678 regulation of epithelial cell proliferation 7.41E-09 2.397907 31.02576 65 1.20E-06 
GO:0005902 microvillus 7.71E-09 4.49066 7.932723 27 1.24E-06 
GO:0050878 regulation of body fluid levels 8.68E-09 2.424222 29.79178 63 1.38E-06 
GO:0090132 epithelium migration 8.95E-09 2.60486 24.5033 55 1.40E-06 
GO:0090130 tissue migration 1.16E-08 2.581401 24.67958 55 1.77E-06 
GO:0048525 negative regulation of viral process 1.74E-08 4.132851 8.725995 28 2.53E-06 
GO:0010631 epithelial cell migration 1.82E-08 2.567568 24.32702 54 2.63E-06 
GO:1990868 response to chemokine 2.20E-08 5.228886 5.81733 22 3.07E-06 
GO:1990869 cellular response to chemokine 2.20E-08 5.228886 5.81733 22 3.07E-06 
GO:0045785 positive regulation of cell adhesion 2.18E-08 2.2257 36.04982 71 3.07E-06 
GO:0019221 cytokine-mediated signaling pathway 2.59E-08 2.379486 29.26293 61 3.57E-06 
GO:0005903 brush border 2.75E-08 3.498254 11.63466 33 3.75E-06 
GO:0043903 
regulation of interspecies interactions 
between organisms 3.06E-08 2.926389 17.01128 42 4.08E-06 
GO:0005201 
extracellular matrix structural 
constituent 3.07E-08 3.399201 12.25165 34 4.08E-06 
GO:0002064 epithelial cell development 3.17E-08 2.690378 20.80136 48 4.19E-06 
GO:0045071 
negative regulation of viral genome 








3.4 Ezh2 deficiency leads to diverse gene expression in different models 
In order to understand the molecular consequences of Ezh2 complete 
deletion in vitro and in vivo, we next used the RNA-sequencing data to investigate 
the transcriptional results between Ezh2 null and Ezh2 wild-type in each model 
system. When comparing Ezh2 null with Ezh2 wild-type genotypes, we dropped 
the total tumor samples, because they were extremely heterogeneous, 
presumably due to the interference of blood cells and endothelial cells, and did not 
produce many significantly differentially expressed genes among the Ezh2 
genotypes (Fig. 3.6a). Sorted tumors had the fewest significantly differentially 
expressed genes while 3D tumor spheroids had the most significantly differentially 
expressed genes (Fig. 3.6b, LFC>0.5 and LFC<0.5, FDR<0.05). Only one gene, 
Ezh2, was shared as differentially expressed for all three systems. In 2D cultures, 
a large cluster of Hox genes was significantly upregulated in Ezh2 null cells 
compared to Ezh2 wild-type cells. However, there was no upregulation of Hox 
genes in 3D and sorted tumors, which indicated that Hox gene de-repression may 
be an effect specific to propagating Ezh2 null cells in 2D systems. In 3D tumor 
spheroids, genes relating to lung cell differentiation such as Spdef, Muc5ac, 
Lamp3, and Trp63 were differentially regulated in Ezh2 null cells, whereas these 
same lung lineage genes were too lowly expressed to detect in 2D cell lines. 
Eleven genes were found to be differentially expressed shared by 3D and sorted 
comparisons. Of these genes, Forkhead Box Protein 2 (Foxp2), encodes for a 
transcription factor vital in embryonic lung development, and was significantly 
higher in Ezh2 null 3D tumor spheroids and in vivo sorted tumors than in Ezh2 
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wild-type counterparts (LFC=5.5, FDR=0.00009 and LFC=1.01, FDR=0.0003 
respectively). Intriguingly, in 2D cultures Foxp2 was not detected in any Ezh2 
genotype by our RNA-sequencing methods. 
GSEA comparing Ezh2 null to Ezh2 wild-type cells from the different 
systems showed the level of complexity of PRC2-mediated gene regulation in the 
different systems (Fig. 3.7a and Table 3.3). The only signature identified to be 
upregulated in Ezh2 null cells in all systems including total tumors was that of 
imprinted genes, supporting our previous observations that imprinted gene 
expression is controlled through Polycomb complexes298. Gene signatures of 
immune responses were enriched in Ezh2 wild-type 3D, sorted and total tumors 
cells, but often enriched in Ezh2 null 2D cells. Similarly, only in 2D cultures did 
Ezh2 null cells show the dramatic up-regulation of the Polycomb target gene 
signatures, and it is notable that many of these signatures were defined in 2D 
systems. As shown previously, HOX gene signatures were unique to Ezh2 null 2D 
cells. Signatures unique to Ezh2 null cells in 3D systems appeared to center 
around lipid and steroid catabolism, whereas in sorted tumor cells, Ezh2 null cells 
had enrichment for growth factor signaling, in line with the vast differences 
between model systems commonly used for cancer research. Collagen and EMT 
signatures were enriched in Ezh2 null cells only in 2D and total tumors, consistent 
with previous study in Eed knockout mouse100, but not in 3D and sorted tumors, 
suggesting that while there is a mesenchymal component to Ezh2 null tumors, the 
extent of EMT is context specific. In addition, in vivo Ezh2 heterozygous tumors 
also had significantly less enrichment for immune cell signatures than Ezh2 WT 
65 
 
and null tumors (Fig. 3.7b and Table 3.4). Furthermore, Ezh2 heterozygous tumor 
cells in vivo had enrichment for histone methylation gene signatures, suggesting a 
feed-back mechanism triggered by haplo-insufficiency for Ezh2 that leads to more 
robust chromatin regulation.  
To accurately assess the changes of immune microenvironment in each 
genotype, RNA-sequencing results of total tumors were used to calculate the 
infiltrations of various immune cells by TIMER2.0299-301. Interestingly, Ezh2 
heterozygous tumors carried significantly more tumor-infiltrating CD8+ T cells, 
monocytes and fewer cancer associated fibroblasts, indicating an anti-tumor 
immune microenvironment of the Ezh2 heterozygous tumors (Fig. 3.7c). In 
contrast, Ezh2 full deletion resulted in fewer naïve B cells, M1 macrophages and 
resting CD4+ memory T cells, and more activated CD4+ memory T cells. When 
focusing on the cell autonomous effects, gene sets related to diverse epithelial cell 
differentiation, embryonic morphogenesis or organ formation, were extensively 
less enriched in 3D and sorted Ezh2 null tumors compared to Ezh2 wild-type (data 
not shown). Ezh2 null sorted tumors were also less enriched in lung cell 
differentiation signature compared to Ezh2 heterozygous sorted tumors, 
suggesting that Ezh2 full deletion brings lung cancer cells to a more poorly 
differentiated state (Fig. 3.7d). It is consistent with the observations that Ezh2 null 
tumors have higher average nuclear grades than the other two genotypes (Fig. 
3.2b). Together, these data show that Ezh2 deprivation drives diverse 





Figure 3. 6 Ezh2 deficiency leads to diverse gene expression in different models 
 
(a) Distributions of differentially expressed genes Ezh2 null vs WT are shown as 
volcano plots in the indicated model systems. FDR cut-off is 0.05 and log2 fold 
change cut-off is 1. (b) Venn Diagram and heatmaps depicting significantly 
differentially expressed genes in Ezh2 null vs. WT cells in the indicated culture 





Ezh2 null are in red, genes lower in Ezh2 null are in blue. Heatmaps depict LFC of 









Figure 3. 7 Ezh2 deficiency leads to diverse enriched gene signatures in different 
models 
(a) Rank ordered gene lists were queried against the MSigDB databases and 
enrichment scores of selected gene signatures enriched in Ezh2 null or Ezh2 WT 
samples in 2D, 3D, in vivo sorted and total tumors were plotted. Size of dots 
estimates false discovery rate (FDR). (b) Rank ordered gene lists were queried 
against the MSigDB databases and enrichment scores of selected gene signatures 







were plotted. Size of dots estimates false discovery rate (FDR). (c) Infiltrations of 
the indicated immune cell types were estimated by TIMER2.0 analysis in the 
samples with indicated genotypes, * indicates p<0.038, ** indicates p=0.00613 and 
*** indicates p<0.00038.  (d) GSEA plots evaluating the changes in the indicated 




















































3.5 Loss of PRC2 activity drives increased FOXP2 expression in normal and 
malignant lung cells 
We next sought to understand if Foxp2 was a direct PRC2 target gene. First, 
we confirmed the expression of FOXP2 in 2D and 3D cells at the mRNA and 
protein levels. Foxp2 was significantly elevated in Ezh2 null cells in both 3D tumor 
spheroids and 2D cultures (Fig. 3.8a and 3.8b). The reason why Foxp2 was not 
detected as significantly changed in 2D cultures by RNA-sequencing is that its 
expression is too low to generate sufficient reads by standard RNA-sequencing 
parameters. In contrast, Foxp2 mRNA levels were significantly higher (>30-fold) in 
Ezh2 null 3D tumor spheroids than in Ezh2 null 2D cells. Furthermore, single cell 
RNA-sequencing showed that Foxp2 was significantly elevated in normal murine 
lung organoids in which Ezh2 was knocked-out, implying that PRC2 governs 
Foxp2 not only in malignant but also in normal lung epithelial cells (Fig. 3.8c). 
Then, to test if EZH2 inhibition leads to de-repression of FOXP2 in human 
samples, we measured FOXP2 mRNA of human cell lines treated with EPZ-6438. 
In line with the discovery in murine cells, inhibition of EZH2 elevated FOXP2 
expression in human cancer lines H460, H2030, A549 and H2009, or transformed 
pulmonary epithelial cells HBEC3KT, BEAS2B and BEAS-KP (Fig. 3.9). 
To interrogate whether EZH2/PRC2 directly regulates Foxp2, we performed 
chromatin immunoprecipitation (ChIP) followed by quantitative PCR (qPCR) on 
mouse Ezh2 wild-type and Ezh2 null 3D spheroids. In the murine system, there 
was a trend of decreased H3K27me3 occupancy at the protein initiation site (ATG) 
and enhancer region of Foxp2 in Ezh2 null cells compared with Ezh2 wild-type 
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cells (Fig. 3.10a). Furthermore, H3K27ac, a marker of active chromatin, was 
enriched at the transcription start site (TSS) and enhancer region of Foxp2 in the 
Ezh2 null spheroids. Similarly, in BEAS-KP cells, an immortalized human bronchial 
epithelial cell line BEAS2B with additional KRASG12V and TP53R175H mutations, 
treatment of EPZ-6438/tazemetostat, the FDA-approved EZH2 inhibitor, caused a 
significant loss of H3K27me3 enrichment at the TSS and enhancer regions of 
FOXP2 (Fig. 3.10b). Correspondingly, H3K27ac was enriched at the TSS and 
enhancer regions of FOXP2 in BEAS-KP with EZH2 inhibition. Intriguingly, in Ezh2 
null and EZH2 inhibited cells, FOXP2 was more enriched at the TSS and enhancer 
regions of FOXP2, indicating that this transcription factor may self-regulate. In 
summary, these data show that FOXP2 is a direct target of the PRC2 complex and 
that loss or inhibition of EZH2 increases FOXP2 expression in normal and 













Figure 3. 8 Loss of PRC2 activity drives increased FOXP2 expression in murine 
lung cancer cells 
 
(a) Relative expression of Foxp2 mRNA in mouse primary 2D tumor cells and 3D 
tumor spheroids with the indicated Ezh2 genotypes determined by RT-qPCR, n=3 
biological replicates for each genotype, * indicates p<0.038. (b) FOXP2 protein 
expression in 2D cells and 3D spheroids of the indicated Ezh2 genotypes was 
examined by immunoblot. H3 is total histone H3 and serves as the loading control. 
(c) UMAP plots depict relative expression of Foxp2 mRNA in murine normal 










Figure 3. 9 Loss of PRC2 activity drives increased FOXP2 expression in human 
normal and malignant lung cells 
 
Expression of FOXP2 mRNA in human lines HBEC3KT, BEAS2B, BEAS-KP, 
H460, H2030, A549, and H2009 with or without EPZ-6438 treatment for 10 days, 
n=3 independent experiments per cell line, * indicates p<0.043, ** indicates 









Figure 3. 10 Loss of PRC2 activity drives increased H3K27ac and decreased 
H3K27me3 at genomic regions of FOXP2 expression 
 
ChIP-qPCR on (a) 3D murine tumor spheroids with indicated genotypes and (b) 
BEAS-KP treated with or without EPZ-6438 for 10 days for Foxp2 transcription 
start site (TSS), translation start site (ATG) and enhancer region using antibodies 
against H3K27me3 and H3K27ac, n=3 biological or technical replicates, * indicates 






3.6 FOXP2 dictates stemness and migratory capacity of lung epithelial cells 
Having established FOXP2 as a direct target of PRC2 in lung epithelial cells, 
we next sought to understand if FOXP2 was driving the phenotypic differences 
observed in Ezh2 null tumor cells. To this end, we overexpressed FOXP2 in normal 
or malignant lung cells, and confirmed increased expression by immunoblot (Fig. 
3.11a). When grown in Matrigel cultures, FOXP2 overexpressing BEAS2B cells 
yielded more and significantly larger organoids than the control cells (Fig. 3.11b-
d). However, the same cells failed to grow in soft-agar experiments, suggesting 
that FOXP2 promoted the stemness of BEAS2B cells without driving oncogenic 
transformation (3.11b). Given the increased metastatic potential of Ezh2 null tumor 
cells, we tested if FOXP2 overexpression changed migratory capability by 
transwell migration assays. First, we confirmed that Ezh2 null mouse tumor cells 
migrated significantly more than Ezh2 WT cells (Fig. 3.12a and 3.12b). Then, in 
human lines HBEC3KT, BEAS2B, H460 and H2030, overexpression of FOXP2 
also produced the cell lines with significantly increased migratory capacity when 
compared to control cell lines (Fig. 3.12c and 3.12d). In line with this observation, 
BEAS-KP with overexpressed FOXP2 grown in Matrigel formed more extensive 
branching structures than control (data not shown). Furthermore, FOXP2 
overexpression also conferred BEAS2B cells resistance to carboplatin and 
etoposide (Fig. 3.13), consistent with the knowledge that cells in more stem-like 
states are relatively resistant to chemotherapy302. To discover the transcriptional 
programs changed by FOXP2 over-expression, we performed RNA-sequencing 
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on FOXP2-overexpressing and control cell lines. GSEA revealed that FOXP2 
overexpression drove transcriptional amplification of many genes associated with 
EMT, cell adhesion, TNFα, RAS signaling, and lung development (Fig. 3.14a and 
Table 3.5), partially overlapping with the altered pathways in 2D mouse cells with 
Ezh2 full deletion. The finding of RAS signaling enrichment was not unique to the 
H460 and H2030 KRAS mutated lines, but also happened in the HBEC3KT and 
BEAS2B KRAS WT lines. Lastly, to link FOXP2 overexpression in human cell lines 
to gene expression changes seen in Ezh2 null spheroids, we examined NDRG4 
and MYCN in FOXP2 overexpressing or EZH2 inhibited H460 and H2030 3D tumor 
spheroid cultures (Fig. 3.14b). These two genes were highly up-regulated in Ezh2 
null spheroids, and are potential PRC2/FOXP2 downstream genes based on the 
ENCODE data303. In these cultures, the combination of FOXP2 overexpression 
and EZH2 inhibition led to the largest increases in NDRG4 and MYCN, confirming 
that these genes are likely regulated by both PRC2 and FOXP2.  
These data on FOXP2 over-expressed cells prompted us to test whether 
FOXP2 inhibition could depress the aggressiveness of lung cancer. Knocking 
down of FOXP2 with two different hairpins in the human H460 cell line remarkedly 
impeded cell growth in 2D cultures (Fig. 3.15a-c). FOXP2 knockdown also led to 
fewer and significantly smaller 3D spheroids formed compared with the control 
shGFP (Fig. 3.15d and 3.15e), suggesting that targeting of FOXP2 could be a 
potential therapeutic avenue in lung cancer. Moreover, the H460 cells with FOXP2 
knockdown migrated significantly less than the control, indicating the 
indispensability of FOXP2 in cell migration (Fig. 3.15f and 3.15g). Altogether, 
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these discoveries identify the pivotal role of FOXP2 in stemness and migration of 
lung epithelial cells, which are regulated in part through the downstream 
























Figure 3. 11 FOXP2 dictates stemness of lung epithelial cells 
 
(a) FOXP2 protein expression in HBEC3KT, BEAS2B, H460, and H2030 cells 
transduced with FOXP2 lentivirus was examined by immunoblot. EV is the empty 
vector control line. H3 is total histone H3 and serves as the loading control. (b) 
Representative images of 3D Matrigel and soft agar cultures seeded with BEAS2B 
cells with or without FOXP2 overexpression, scale bar = 1000µm for Matrigel 
cultures and 100µm for soft-agar cultures. (c) Average diameters and (d) count 
numbers of BEAS2B 3D organoids with or without FOXP2 overexpression, n=3 










Figure 3. 12 FOXP2 dictates migratory capacity of lung epithelial cells 
 
(c) Representative images and (b) average numbers of migrated cells in Ezh2 wild-
type UK803 and Ezh2 null UK777 mouse lines, n=4 technical replicates, ** 
indicates p=0.00167. (c) Representative images and (d) average numbers of 
migrated cells in HBEC3KT, BEAS2B, H460, and H2030 cells with or without 














Figure 3. 13 FOXP2 overexpression confers resistance to chemotherapy 
 
Normalized dose-response to carboplatin and etoposide of BEAS2B cells with or 
without FOXP2 overexpression, *** indicates p<0.0001 comparing models by extra 























Figure 3. 14 FOXP2 overexpression cooperates with PRC2 to regulate gene 
expression 
 
(a) Rank ordered gene lists were queried against the MSigDB databases and 
enrichment scores of selected gene signatures enriched in FOXP2 over-
expressing cell lines relative to EV lines were plotted. Size of dots estimates FDR. 
(b) Normalized mRNA expression of FOXP2, NDRG4, and MYCN with or without 







Figure 3. 15 FOXP2 knockdown suppresses cell proliferation, organoid formation 
and migration of lung cancer 
 
(a) FOXP2 protein expression in H460 cells transduced with indicated small 
hairpins was examined by immunoblot. shGFP is the control cell line. H3 is total 
histone H3 and serves as the loading control. (b) Crystal violet growth assays were 





performed on 2D H460 cells with or without FOXP2 knockdown at indicated days 
of culture, n=6 independent experiments, ** indicates p<0.0024, *** indicates 
p<0.001. (c) Representative whole well images of crystal violet stained H460 cells 
with indicated small hairpins 6 days after seeding. (d) Average diameters and (e) 
counts of 3D H460 spheroids with or without FOXP2 knockdown, n=6 independent 
experiments, ** indicates p=0.007, *** indicates p<0.001 compared to shGFP 
spheroids. (f) Average percentages normalized to shGFP and (g) representative 
images of migrated cells in H460 with or without FOXP2 knockdown, n=4 technical 










































3.7 Polycomb deficiency drives BET and histone de-methylase inhibitor 
sensitivity 
We next aimed to identify epigenetic therapeutic vulnerabilities of PRC2-
deficient KRAS+/Trp53-null lung adenocarcinomas. We reasoned that because 
Ezh2 null tumors were most aggressive, methods to stabilize PRC2 marks or 
prevent reading of H3K27ac marks could allow for ‘re-normalization’ of the 
aberrant epigenetic state. Therefore, we focused our efforts on testing the histone 
demethylase inhibitor GSK-J4 and BET inhibitor JQ1 (Fig. 3.16a). Diverse culture 
models were used to detect the sensitivities of these epigenetic inhibitors, including 
in vitro systems of 2D standard cell culture, 3D Matrigel air-liquid interface 
transwell culture, and in vivo nude mouse allografts and genetically modified 
mouse model autochthonic tumors. In 2D monolayer cell culture, there were no 
differences in half maximal inhibitory (IC50) values among the Ezh2 wild-type, 
heterozygous, and null tumor cells treated with GSK-J4 or JQ1 (Fig. 3.16b). 
However, when propagated in 3D air-liquid interface Matrigel cultures, Ezh2 null 
spheroids were more susceptible to GSK-J4 and JQ1 when compared with Ezh2 
wild-type spheroids (Fig. 3.16c and 3.16d). Ezh2 heterozygous spheroids were 
similarly sensitive to JQ1 as Ezh2 null, but only modestly sensitive to GSK-J4. The 
lack of consensus between 2D and 3D cultures prompted us to investigate drug 
vulnerabilities in vivo. 3D tumor spheroids were isolated and grafted 
subcutaneously onto immunocompromised mice. Intriguingly, consistent with the 
3D culture system, Ezh2 null allografts were growth-inhibited more strongly than 
Ezh2 wild-type after GSK-J4 and JQ1 treatment in nude mouse, while the 
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therapeutic effect of JQ1 on Ezh2 heterozygous allografts was between the former 
two genotypes (Fig. 3.17a and 3.17b).  
To test if JQ1 could decrease tumors growing in the native lung 
microenvironment, we treated autochthonous tumor bearing mice with JQ1 and 
measured changes in tumor volume by magnetic resonance imaging (MRI). Seven 
days of JQ1 treatment reduced the volumes of the lung tumor nodules in Ezh2 null 
GEMMs, while tumors continued to grow in the placebo group (Fig. 3.17c and 
3.17d). An additional seven days of JQ1 administration was sufficient to retain 
tumors in their regressed state, though no additional tumor burden reduction was 
observed. One mouse harboring Ezh2 heterozygous tumors also showed tumor 
reduction with JQ1, mirroring results observed in 3D and allograft (data not shown). 
To further explore the clinical significance of the drug vulnerability discoveries from 
murine tumors, we used several KRAS mutated human non-small cell lung cancer 
lines. Drug synergy matrix experiments demonstrated abundant synergy or 
potently additive effect when combining JQ1 with EPZ-6438 in H2030, H2009, and 
also BEAS-KP (Fig. 3.18a). Additionally, knocking down of EZH2 sensitized the 
human line H2030 to JQ1 (Fig. 3.18b and 3.18c), and such sensitization was more 
observable in 3D spheroid culture than 2D culture in H460 (Fig. 3.18d). 
The differential response to BET inhibitor inspired us to interrogate whether 
FOXP2 was involved in its therapeutic effect in EZH2-deficient cells. First, we 
performed RNA-sequencing on the 3D tumor spheroids and allografts treated with 
JQ1, which revealed that BET inhibition led to decreased Foxp2 expression 
primarily in Ezh2-insufficient cells (Fig. 3.18e). c-Myc, one of the more common 
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genes changed by JQ1 304, was also decreased in expression in the allograft, 
which confirms efficacy of the drug. Genes upregulated by FOXP2, including the 
PRC2/FOXP2 downstream genes Mycn and Ndrg4, and genes associated with 
lung differentiation, such as keratin genes, Sftpb and Scgb3a2, were also 
repressed by JQ1 in the Ezh2 null allograft setting. RT-qPCR on mouse 3D tumor 
spheroids also showed that 25nM JQ1 increased Foxp2 expression in Ezh2 wild-
type but slightly reduced it in Ezh2 heterozygous and null spheroids (Fig. 3.18f). 
Foxp2 was significantly inhibited by 100nM JQ1 in Ezh2 heterozygous and null 
tumor spheroids, but not in Ezh2 WT tumor spheroids, which may explain the 
difference in drug sensitivity among the genotypes. Similarly, in the H2030 cell line, 
knock-down of EZH2 which we previously showed conferred sensitivity to JQ1, led 
to increased FOXP2 expression (Fig. 3.18g). Treatment of these lines with JQ1 
showed that FOXP2 levels were significantly decreased in the shEZH2 lines, but 
not in the shGFP line, again suggesting that regulation of FOXP2 correlated to the 
increased sensitivity of cells to JQ1. Taken together, these data indicate that EZH2 
blockade confers sensitivity to BET inhibition and demethylase inhibition in lung 









Figure 3. 16 Polycomb deficiency drives BET and histone de-methylase inhibitor 
sensitivity in murine 3D culture in vitro 
 
(a) Schematic depicting the mechanisms to restore epigenetic states lost in PRC2-
deficient tumors. (b and c) GSK-J4 and JQ1 dose-response curves of (b) 2D 
primary cells from different donor mice, n=5 Ezh2 WT, n=6 Ezh2 heterozygous and 
n=6 Ezh2 null; and (c) 3D spheroids, n=7 Ezh2 WT, n=5 Ezh2 heterozygous and 
n=5 Ezh2 null, *** indicates p=0.0004, ** p=0.0023 for Ezh2 WT vs Ezh2 null. (d) 
Images of placebo-, GSK-J4- and JQ1-treated spheroids of the indicated Ezh2 
genotypes. (b) Wet weights of placebo-, GSK-J4- and JQ1-treated in vivo allografts 









Figure 3. 17 Polycomb deficiency drives BET inhibitor sensitivity in murine 
tumors in vivo 
 
(a) Changes in volumes of allografts in mice treated with GSK-J4 and JQ1 relative 
to changes in volumes of allografts in placebo treated mice are plotted over time. 
Donor mice for GSK-J4 experiments were n=5 Ezh2 WT, n=5 Ezh2 heterozygous 
and n=4 Ezh2 null; donor mice for JQ1 experiments were n=5 Ezh2 WT, n=5 Ezh2 





compared with Ezh2 WT repeated measures ANOVA. (b) Wet weights of placebo-
, GSK-J4- and JQ1-treated in vivo allografts of the indicated Ezh2 genotypes. (c) 
Quantification of relative tumor volume change after 1 week and 2 weeks of 
placebo or JQ1 treatment of Ezh2 null tumor bearing mice, ** indicates p<0.005 
repeated measures ANOVA. (d) Representative magnetic resonance images of 





















Figure 3. 18 EZH2 inhibition synergizes with BET inhibition in mouse and human 
cancers 
 
(a) Heatmap of Bliss synergy scores of EPZ-6438 combined with JQ1 in H2030, 






































produce an average matrix. Overall Bliss synergy scores were 6.78, 5.84, and 
6.47, respectively. Most synergist area Bliss scores were 8.56 for H2030, 10.57 
for BEAS-KP, and 10.05 for H2009. (b) H2030 and H460 2D cells with or without 
EZH2 knock-down were examined for the expression of the indicated proteins by 
immunoblot. H3 indicates total histone H3 and is the loading control. (c) 
Normalized dose-response to JQ1 of H2030 cells with or without EZH2 knock-
down, *** indicates p<0.0003 comparing models by extra sum-of-squares F 
statistic. (d) Relative cell survival of H460 cells with or without EZH2 knock-down 
in 3D (n=3) and 2D (n=4) cultures to JQ1 treatment compared with vehicle control. 
(e) Heatmap depicting log-fold change (LFC) in gene expression after JQ1 
treatment in the indicated genotypes relative to control, n=1 matched pair of JQ1 
treated and vehicle treated for each column. (f) Expression of Foxp2 mRNA in 
mouse 3D tumor spheroids treated with JQ1 25nM and 100nM for 7 days 
normalized to expression in the vehicle control treated culture for the indicated 
Ezh2 genotypes, * indicates p=0.012, ** indicates p=0.001. (g) Expression of 
FOXP2 mRNA on H460 with or without EZH2 knockdown treated with vehicle or 













3.8 High EZH2 correlates with low H3K27me3 and high FOXP2 and predicts 
advanced lung cancer 
To extend our finding to human lung cancer patient samples, we performed 
immuno-histochemical staining for EZH2, H3K27me3, and FOXP2 on lung cancer 
tissues from 233 patients, including 92 adenocarcinoma (ADC) cases, 104 
squamous cell carcinoma (SCC) cases, 24 adenosquamous (ADSCC) cases and 
13 cases of poorly differentiated tumors including 1 sarcomatoid tumor. Consistent 
with previous research214,269, the H3K27me3 stain was respectively higher in ADC 
than SCC, while EZH2 had the opposite pattern of being higher in SCC and lower 
in ADC (Fig. 3.19a). FOXP2 expression was variable in ADC samples, but often 
found to be high in poorly differentiated tumors. Focusing on only ADC and poorly 
differentiated lung tumors, we observed that well differentiated tumors often had 
high H3K27me3, low EZH2 and low FOXP2 expression, while poorly differentiated 
tumors had lower H3K27me3, higher EZH2 and sometimes had higher FOXP2 
expression (Fig. 3.19b). Consistent with these staining patterns, in all ADC and 
poorly differentiated samples, EZH2 expression was slightly inversely correlated 
to H3K27me3 expression and was strongly positively correlated to FOXP2 
expression (Fig. 3.19c). We next binned samples into groups that had high 
expression or low/negative expression of EZH2 and H3K27me3 and found a 
significant enrichment of EZH2 high and H3K27me3 low patterns in poorly 
differentiated tumors compared to well differentiated tumors (Fig. 3.19d). 
Similarly, by assessing the percentage of positive nuclei, poorly differentiated 
ADCs had the higher EZH2 and lower H3K27me3 expression compared with well 
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or moderately differentiated tumors. FOXP2 staining patterns showed that well 
differentiated tumors could express FOXP2, but that FOXP2 expression was also 
higher in poorly differentiated tumors than in moderately differentiated tumors. 
EZH2 and H3K27me3 decoupling could be driven by multiple factors, and one 
likely factor is that in highly proliferative tumors, although EZH2 may be increased, 
availability of  the methyl donor, S-adenosyl methionine (SAM), may be more 
scarce100. To examine this hypothesis of SAM levels influencing PRC2 stability 
and activity, 500μM SAM was added to the culture media of human lines H460, 
A549 and BEAS-KP for 6 days. As expected, the cell lines treated with SAM all 
showed higher H3K27me3, and meanwhile had lower EZH2 and FOXP2 
compared to the control (Fig. 3.20a-c). Treating Ezh2 wild-type mouse line UK803 
with SAM led to a similar decoupling of EZH2 and the H3K27me3 mark (Fig. 
3.20d).  These data suggest that when SAM is abundant, which may be the case 
in slowly growing more well differentiated tumors, PRC2 activity is high and EZH2 
is down-regulated.  In more quickly proliferating tumors, EZH2 is upregulated but 
a lack of SAM leads to an overall lower level of H3K27me3 mark.   
Although a limited sample size and unknown mutational states, patients 
with high expression of FOXP2 displayed a shorter survival than FOXP2 low 
patients when followed up to 30 months (Fig. 3.21A). To increase the power of 
this analysis, we queried published RNA-sequencing data from the Cancer 
Genome Atlas using KM-Plotter on 504 lung adenocarcinoma samples. Higher 
EZH2 expression correlated with significantly worse prognosis in lung 
adenocarcinoma up to 250 months after diagnosis (Fig. 3.21b and 3.21c). 
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Moreover, higher FOXP2 expression correlated with significantly shorter overall 
survival up to 30 months after diagnosis, and shorter relapse-free survival 250 
months post diagnosis (Fig. 3.21d and 3.21e). In summary, in lung cancers, EZH2 
expression decouples from PRC2 activity, and a pattern of high EZH2, low 
H3K27me3 and high FOXP2 is enriched in poorly differentiated advanced lung 









Figure 3. 19 EZH2 correlates with high FOXP2 expression, low H3K27me3 and 
poorly differentiated lung tumors 
 
(a) Representative images of lung adenocarcinoma specimens defined as well, 
moderately, and poorly differentiated stained for the indicated markers, scale 
bar=100µm. (b) Box and whisker plots depict percentage of positively stained 
tumor nuclei in ADC, ADSCC, poorly differentiated tumor and SCC specimens for 
the markers EZH2, H3K27me3 and FOXP2. (c) Correlation between EZH2 and 






positively stained tumor nuclei in primary lung cancer specimens. Pearson’s 
correlation coefficients and p values are shown. (d) Average percentage of 
positively stained tumor nuclei for the indicated markers in lung cancer specimens 
defined as well, moderately, and poorly differentiated, * indicates p<0.043 and ** 



























Figure 3. 20 S-Adenosyl methionine regulates PRC2 stability and activity 
 
(a) H460, (b) A549 and (c) BEAS-KP 2D cells with or without 500μM SAM 
treatment for 6 days were examined for the expression of the indicated proteins 
by immunoblot. H3 indicates total histone H3 and is the loading control. (d) 2D 
Ezh2 wild-type UK803 with or without 500μM SAM treatment for 6 days were 
examined for the expression of the indicated proteins by immunoblot. H3 











Figure 3. 21 EZH2 and FOXP2 correlates with worse prognosis in lung 
adenocarcinoma 
 
(a) Kaplan-Meier survival curves for the FOXP2 high and FOXP2 low TMA 
samples as measured by immunohistochemistry 30 months post diagnosis, groups 
were split equally at median expression, p value was calculated by Mantel-Cox 
log-rank test. (b) Kaplan-Meier overall survival curves and (c) relapse-free survival 
curves for the EZH2 high and EZH2 low tumors as measured by RNA-sequencing 
250 months post diagnosis, groups were split equally at best cut-off, p value was 
calculated by Mantel-Cox log-rank test. (d) Kaplan-Meier relapse-free survival 
curves and (e) overall survival curves for FOXP2 high and FOXP2 low tumors as 
measured by RNA-sequencing 250 months post diagnosis, positive and negative 
groups were determined by best cut-off, p value was calculated by Mantel-Cox log-
rank test. 




3.9 Summary and discussion 
Here, we found that haplo- and full-insufficiency of the Polycomb 
Repressive Complex 2 (PRC2) had divergent outcomes in KRAS-driven lung 
cancers, further supporting the hypothesis that EZH2 can act as an oncogene or 
tumor suppressor in different cellular contexts. Building upon previous findings of 
de-coupling of EZH2 from PRC2 catalytic activity214,269-271, we discovered that 
EZH2 and its enzymatic substrate H3K27me3 were inversely correlated in lung 
adenocarcinoma samples, and that poorly differentiated tumors were often EZH2-
high/H3K27me3-low. Furthermore, while Ezh2 heterozygous lung tumors were 
less aggressive than Ezh2 wild-type tumors, homozygous deletion of Ezh2 
triggered a re-programming of tumors to an aggressive metastatic state 
characterized by high expression of the embryonic transcription factor FOXP2. In 
patient samples, FOXP2 expression predicted significantly shorter relapse-free 
survival. Several previous studies have shown that loss of PRC2 activity can 
reprogram cells into more aggressive states in medulloblastoma and lung 
cancers100,214,305, suggesting that in many cancer settings, the most aggressive 
state is characterized by a loss of PRC2 activity. Unlike a model that drove PRC2 
loss through Eed deletion and observed acquisition of a mucinous phenotype100, 
our Ezh2-deletion model did not have mucinous differentiation in vivo, suggesting 
that a non-PRC2 role of EZH2 or the residual activity of PRC2-EZH1 may control 
acquisition of the mucinous phenotype. Our data demonstrated that over-dose of 
SAM could cause the degradation of EZH2 together with tri-methylation 
accumulation, thus leading to the decoupling. Our future research is focused on 
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understanding its physiological or pathophysiological metabolic mechanism 
through which SAM supply is regulated, and whether this process can be reversed 
for therapeutic intervention.  
This interesting dosage effect of Ezh2 is distinct from cases where 
heterozygosity shows genetic advantage, such as mutations in DICER, PTEN and 
ARID1A306,307. Rather, in the case of Ezh2, heterozygous mutations may yield 
decreased cell fitness and be selected against, thus never allowing the opportunity 
for loss of heterozygosity that would yield the fully mutant phenotype we generated 
here. Another case that may be similar is mono- vs. bi-allelic deletion of the 
chromatin enzyme Setd2, which has both histone and non-histone substrates308. 
It was found that mono-allelic Setd2-deficient cells retained histone methylation 
(H3K36me3) but lost tubulin methylation (αTubK40me3), while bi-allelically 
deficient cells lost both marks309. Non-histone substrates for PRC2 include talins 
and the transcription factor STAT3310,311, and further studies could query if Ezh2 
haploinsufficiency influences these functions. Regardless of the underlying 
mechanism, this discovery suggests that unlike inhibitors targeting driver 
oncogenes, a sub-maximal dose of EZH2 inhibition or a strategy to decrease 
EZH2 protein level may target the most viable therapeutic window for lung cancer.  
Furthermore, our data strongly suggest that a combination of EZH2 
inhibition and BET inhibition will be synthetically lethal in KRAS-driven lung 
cancers. Using both genetic manipulation and pharmacological approaches, we 
observed that Ezh2-null tumor spheroids, allografts and autochthonous lung 
tumors were sensitive to the BET inhibitor JQ1. Furthermore, there was strong 
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synergy between the FDA-approved EZH2 inhibitor EPZ-6438 and JQ1 in a variety 
of human lung cancer cells. Mechanistically, we identified that FOXP2, which was 
previously identified as a key regulator of embryonic lung progenitor cells287 was 
a modulator of response to BET inhibitors. We confirmed that FOXP2 was a direct 
target of PRC2-mediated gene silencing in lung epithelial cells, and that enforced 
expression of FOXP2 increased stemness and migration of lung epithelial cells. 
These phenotypes were not unique to KRAS-mutated cells – FOXP2 over-
expression in normal lung epithelium led to increased migration, increased growth 
in Matrigel cultures and up-regulation of genes involved in RAS signaling. Our 
research focused on KRAS+/TP53-null lung cancers, and whether the EZH2i/BETi 
synergy will be viable in other major lung cancer genotypes will require further 
research. 
It is notable that our drug response findings and the identification of FOXP2 
were discovered in vitro only due to the use of 3D tumor spheroid cultures. We 
found that murine 2D cell lines had extremely high levels of S-phase and down-
regulation of genes involved in lung lineage determination when compared to 3D 
tumor spheroids, which showed retention of lung specification transcriptional 
programs. This finding is consistent with the belief that 3D cultures are able to 
retain more characteristics of the native tissue from which they were derived, and 
demonstrate the vast differences between the same cells cultured in two 
dimensions versus those in three dimensions. The outcomes of loss of PRC2 
activity in 3D and 2D cells were also divergent. In the Ezh2 null genotype, 2D cell 
lines had marked de-repression of Hox genes, but in 3D tumor spheroids, Ezh2 
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null cells were able to continue to repress Hox genes and instead showed de-
repression of Foxp2. Clearly, Hox genes are Polycomb targets in mammalian 
cells297,312, but our studies suggest that in lung cancer cells, dysregulation of HOX 
genes in PRC2-deficient settings may only happen in 2D cell lines. Other studies 
have demonstrated that murine tumor spheroids can be used to build genetically 
diverse bio-banks that can then be used for in vitro and in vivo studies including 
immunotherapy studies313,314. Even with a traditional human 2D cell line, a recent 
study demonstrated that a CRISPR-based screen identified more genes relevant 
to human cancer when the screen was performed in 3D spheroid cultures226. 
Together, these findings underscore the power of using 3D systems for genetic, 












CHAPTER 4. EZH2 INHIBITION CONFERS PIK3CA-DRIVEN LUNG TUMORS 
ENHANCED SENSITIVITY TO PI3K INHIBITION 
4.1 Brief introduction 
Large scale studies of tumor genetics have uncovered that alterations in the 
Phosphoinositide 3-kinase (PI3K) pathway are prevalent in cancer.186 In particular, 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) 
encoding the catalytic subunit p110α of the PI3K complex is highly mutated and 
amplified in numerous cancer types, including lung cancer. The signaling pathways 
downstream of PI3K include AKT and mTOR, and genetic alterations of PIK3CA 
represent one of the oncogenic drivers of lung cancer, along with activating 
mutations in EGFR and KRAS.315 Despite the recent development of specific PI3K 
inhibitors, there is still no FDA-approved precision medicine option for this genetic 
subclass of lung cancer. In fact, the early clinical trials of PI3K inhibitors on lung 
cancers had underwhelming results and were ended early, though the patient 
population included both patients with the activation of PIK3CA and those with 
loss-of-function mutation in the PI3K negative regulator phosphatase and tensin 
homolog (PTEN). 316-318      
 
It is widely believed that in addition to genetic mutations, epigenetic 
changes may be required for maintenance of the cancer cells in proliferative and 
drug-resistant states. One attractive way to target tumor-related growth programs 
is through inhibition of epigenetic regulators of gene expression. A group of master 
regulators of chromatin state in stem cells and cancers are termed the Polycomb 
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Repressive Complexes (PRCs)319. Research has shown that histone methylation 
or ubiquitylation mediated by these PRCs can affect higher order chromatin 
structure, rendering areas in the genome inaccessible to transcriptional 
machinery320. Specifically, the complex PRC2 often contains EZH2 as the 
methyltransferase that tri-methylates histone H3 at lysine 27 (H3K27me3), 
silencing gene expression319,321 Recently, a small molecule inhibitor of the 
epigenetic histone methyltransferase EZH2, tazemetostat, was FDA-approved in 
solid tumors including epithelioid sarcoma and follicular lymphoma, and several 
others are being used in pre-clinical models and clinical trials.322 While some data 
have suggested that EZH2 inhibitors will synergize with immunotherapies or other 
chemotherapies, it is unknown if tumors mutant for the PI3K pathway would benefit 
from it. Furthermore, it also remains unknown if PI3K inhibitors will synergize well 
with EZH2 inhibitors in lung cancer. 
 
In this study, we reveal that the PIK3CA-mutant or amplified lung cancer 
cells were more sensitive to EZH2 inhibition. PIK3CA E545K, the most common 
mutation in lung cancer, presents a modest transformation capacity along with p53 
loss in lung epithelial cells, and drove lung adenocarcinoma formation 
autochthonously. Also, we discover that EZH2 inhibition synergized with PI3K 
inhibition in human cancer cells in vitro and in vivo. This study sheds light on a 





4.2 PIK3CA mutated or amplified cell lines have increased sensitivity to EZH2 
inhibition 
We first queried the cBioportal database to understand the current 
landscape of PIK3CA mutations in lung cancer patients.323,324  Leveraging data 
from The Cancer Genome Atlas (TCGA) pan-lung cancer dataset, we observed 
that 24% of lung tumors harbored PIK3CA alterations, the majority of which were 
gene amplifications with or without missense mutations (Figure 4.1a). Strikingly, 
this patient subset was nearly mutually exclusive to those with KRAS genetic 
alterations (log2 odds ratio -1.819, q-value <0.0001), the latter of which were 
mainly missense mutations. Overall, 509 (44%) out of the 1144 samples queried 
had genetic aberrations in either PIK3CA or KRAS, or both. Among these patients, 
lung adenocarcinoma (LADC) predominantly harbored genetic mutations, which 
were mainly KRAS mutations. (Figure 4.1b) On the contrary, the majority of lung 
squamous cell carcinoma (LSCC) samples had amplifying PIK3CA. Although 
LADC had a much lower frequency of PIK3CA alterations, the proportion of 
PIK3CA mutations were relative higher than the amplification in LADC. The most 
common mutation in PIK3CA genetic region is a point mutation that yields a 
substitution of glutamic acid by lysine at position 545 and this specific change 
(PIK3CA E545K) was observed in 29 (10.5%) of patients with PI3K alterations 
(Figure 4.1c).  
 
In order to test the effects of EZH2 inhibition on lung cancer cells with 
differing PIK3CA and KRAS statuses, we screened 16 lines for sensitivity to the 
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EZH2 inhibitor GSK126. All the cell lines with IC50 values below 7µM were reported 
to be PIK3CA mutant or amplified (Figure 4.2).  In contrast, the cell lines mutant 
for KRAS or NRAS, but without any known alteration of PIK3CA had higher IC50 
values, up to 17.4µM, for GSK126.  Two cell lines, H2126 and H520, do not have 
mutations in either RAS or PIK3CA and those cell lines had intermediate IC50 
values. Overall, PIK3CA mutant and amplified cell lines had an average IC50 value 
of 6.1µM, while cell lines mutant for RAS and wild-type (WT) for PIK3CA had an 
average IC50 value of 10.6µM, a 1.74-fold difference (Figure 4.2). This result 
suggests a window of vulnerability for PI3K-driven cancers to be targeted by EZH2 
inhibition. There were two notable exceptions to the genotype-sensitivity 
correlation in our dataset, H460 and H1975. H460, which has a PIK3CA E545K 
mutation, also harbors a mutation in LKB1/STK11, which through AMPK activates 
downstream mTOR signaling as PI3K does. In addition, H1975, an EGFR-driven 
line, which is also PIK3CA mutant and LKB1 mutant, appears to be insensitive to 
GSK126. None of the GSK126-sensitive cell lines have LKB1 mutations, implying 
the combination of mutant/amplified PIK3CA and WT LKB1 may be the most 












Figure 4. 1 Landscape of PIK3CA mutations in lung cancer patients 
 
(a) Landscape of PIK3CA and KRAS gene alterations in cBioPortal database 
showing 1144 non-small cell lung cancer patients. (b) Alteration frequencies of 
PIK3CA and KRAS in LADC and LSCC from cBioportal database. (c) Lollipop plots 















Figure 4. 2 PIK3CA mutated or amplified cell lines have increased sensitivity to 
EZH2 inhibition 
 
Non-linear regression of cell line survival in response to the EZH2 inhibitor 
GSK126 is plotted for each cell line separately (left) and three groups as indicated 












4.3 PIK3CA-E545K induces moderate transformation in lung epithelial cells 
We next sought to learn about the oncogenic potential of the most common 
mutation of PIK3CA in lung cancer, PIK3CA-E545K. BEAS2B cells are 
immortalized with SV40, and therefore should have inactivation of both RB and 
p53 pathways.325 We first introduced a mutated form of p53, p53-R175H, to 
BEAS2B cells to both ensure that WT p53 function is completely abrogated and to 
possibly introduce some gain-of-function roles of mutant p53, and we used this as 
our base cell line.326 We then inserted either WT PIK3CA, mutated PIK3CA-
E545K, or mutated KRAS-G12V into the base lines (Figure 4.3a) The integration 
of the vectors was confirmed by PCR of genomic DNA with primers that included 
a region specific to the targeting virus (Figure 4.3b). We next tested the functional 
activity of PI3K pathway in these modified BEAS2B lines by detecting phospho-
AKT/total AKT ratio downstream of PI3K. Immunoblots showed that BEAS2B with 
PIK3CA-E545K insertion had drastically increased level of phospho-AKT than the 
control empty vector (Figure 4.3c). Introduction of WT PIK3CA and KRAS-G12V 
slightly upregulated phospho-AKT. Calu3, a lung cancer cell line with PIK3CA 
amplification and p53 mutation, had the highest AKT phosphorylation level of all 
cell lines tested.  
 
To dissect the transformation capacity of PIK3CA-WT, PIK3CA-E545K and 
KRAS-G12V, we performed soft agar colony formation assay on these four lines. 
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It showed that KRAS-G12V-transformed BEAS2B cells formed many more 
colonies than the other three cell lines, though due to variability of the experiment 
the normalized data were not significant (Figure 4.4a and 4.4b). PIK3CA-E545K 
cells yielded slightly more colonies than the control and PIK3CA-WT BEAS2B 
cells, but again this result was not significant. However, in 3-dimensional (3D) 
Matrigel culture, KRAS-G12V cells yielded the most organoids and both PIK3CA-
E545K and KRAS-G12V lines developed significantly more organoids than the 
control cells (Figure 4.5a and 4.5b). There were no obvious differences in 
organoid counts between control and PIK3CA-WT cells. Together, these findings 

















Figure 4. 3 PIK3CA-E545K mutation activates downstream pathways in lung 
epithelial cells 
 
(a) Schematic of modifications in BEAS2B cells with indicated vector introduction. 
(b) Recombination PRC of genomic DNA with primers covering a region specific 
to the targeting virus indicated. (c) Immunoblot probing phospho-AKT and total 













Figure 4. 4 PIK3CA-E545K does not affect colony formation in soft agar in lung 
epithelial cells 
 
(a) Representative whole well images and (b) colony counts of soft agar colony 



















Figure 4. 5 PIK3CA-E545K induces moderate transformation in lung epithelial 
cells in 3D Matrigel culture 
 
(a) Representative whole well images and (b) colony counts of 3D Matrigel culture 








4.4 Pik3ca-E545K with p53 loss drives lung adenocarcinomas in a novel mouse 
model 
Next, in order to study the role of PIK3CA E545K mutation in the 
tumorigenesis in vivo, we obtained the genetically engineered mouse model 
(GEMM) that harbored floxed alleles of Trp53 and a Lox-stop-Lox conditional 
activating allele encoding Pik3ca-E545K knocked into the endogenous Pik3ca 
(Figure 4.6a). We administered adeno-Cre virus via intranasal instillation to 
cohorts of mice and Monitored mice for signs of tumor burden. At more than 52-
weeks post adeno-Cre, five out of seven mice analyzed (71.4%) had frank lung 
tumors that were uniformly adenocarcinoma by histological examination (Figure 
4.6b, 4.7a and 4.7b). These tumors had high expression of pro-surfactant protein 
C (SPC) and no detectable expression of acetylated tubulin, KRT5, SOX2 or club 
cell secretory protein (CCSP), suggesting that the tumors were adenocarcinoma 
probably originated from alveolar type 2 (AT2) progenitor cells. Some tumors had 
light and sporadic staining for MUC5AC, but no obvious goblet cell differentiation. 
The antibodies used were validated on tracheal and esophagus sections (Figure 
4.7c). The prolonged latency of this model compared with Kras-G12D/p53-loss 
mouse model is consistent with our results in the BEAS2B cell line, suggesting that 
PIK3CA-E545K is a relatively weak oncogene relative to oncogenic KRAS. It was 
also accordant with the observation that PIK3CA mutations were more frequently 
seen than amplified PIK3CA in LADC, in spite of the prevalence of PIK3CA 




We next isolated tumor cells from the Pik3ca/p53 GEMMs and grew the 
cells in specialized air-liquid-interphase 3D Matrigel cultures. These types of 
cultures have allowed for successful propagation of every murine lung cancer 
model so far studied, including Kras-G12D/Trp53-null, Kras-G12D/Lkb1-null, 
EGFR-L858R/T790M and Lkb1-null/Pten-null tumor models. Initially the 
Pik3ca/p53 tumor cells grew as organoids that resembled the structure of lung 
alveoli. Upon passaging, it was clear that the model did not have the robust growth 
capacity observed from our other tumor models. Given the alveolar structure of the 
tumor organoids, we reasoned that they may grow better with neonatal lung 
mesenchymal cells, which help to support alveolar cells. Co-culturing with these 
mesenchymal cells, either as a monolayer on the bottom of the transwell or mixed 
into Matrigel, allowed for improved growth of the tumor cells so that several models 
could be established (Figure 4.8).  These models will be important for future drug 
studies. Altogether, Pik3ca E545K mutation with p53 loss drove lung 












Figure 4. 6 Pik3ca-E545K with p53 loss drives lung cancer in a novel mouse 
model 
 
(a) Schematic of Pik3ca-E545K LSL/+;Trp53 fl/fl cohorts of mouse models. (b) Tumor-





















Figure 4. 7 Pik3ca-E545K with p53 loss drives autochthonous LADC 
 
(a) H&E and IF analysis with the indicated probes of Pik3ca-E545K LSL/+;Trp53 fl/fl 
murine tumor sections 55 weeks post infection. (b) H&E and IF analysis with the 
indicated probes of Pik3ca-E545K LSL/+;Trp53 fl/fl murine tumor sections 64 weeks 
post infection. (c) Antibody validation of IF analysis with the indicated probes of 









Figure 4. 8 Pik3ca-E545K/p53-loss tumors form alveolar tumor organoids 
 












4.5 EZH2 inhibition synergizes with PI3K inhibition in lung cancer 
Given the significant increase in sensitivity of PIK3CA mutant/amplified lung 
cancer cells to EZH2 inhibitor GSK126, we reasoned that a combination of the 
PI3K inhibitors, such as copanlisib, and the EZH2 inhibitors could allow for a more 
potent therapeutic response. During the course of our studies, the EZH2 inhibitor 
tazemetostat (EPZ-6438) became FDA approved and therefore, we included this 
second EZH2 inhibitor in our drug synergy studies. We identified that both GSK126 
and EPZ-6438 were very effective at reducing the PRC2 histone mark, H3K27me3, 
and that copanlisib was very effective at reducing the levels of phospho-AKT in 
both Calu3 and Sw1573 lung cancer cells(Figure 4.9a). Of note, Sw1573 cells 
have PIK3CA-K111E and KRAS-G12C mutations, while Calu3 cells have PIK3CA-
amplification but no RAS mutation and showed substantially higher phospho-AKT 
than Sw1573. Intriguingly, copanlisib combined with EPZ-6438 led to a lower level 
of phospho-AKT than copanlisib alone or combined with GSK126. 
 
In order to examine the synergy of EZH2 inhibitor and PI3K inhibition, we 
performed dose synergy matrix experiments and analyzed the data with 
SynergyFinder2.0.249 The results showed that copanlisib had synergistic effect 
with EZH2 inhibitors GSK126 and EPZ-6438 in both Calu3 and Sw1573 cells 
(Figure 4.9b). Next, we studied it in BEAS2B cells with control empty vector, 
PIK3CA WT, E545K mutation, or mutated KRAS-G12V. It showed that PIK3CA 
WT or mutation did not change the sensitivity to GSK126, while KRAS mutation 
conferred resistance to GSK126 in BEAS2B cells (Figure 4.10). Moreover, 
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copanlisib synergized with GSK126 and EPZ-6438 in all the modified BEAS2B 
cells except for copanlisib with EPZ-6438 in KRAS-G12V line, which showed an 
antagonistic effect (Figure 4.11a and 4.11b). Mechanistically, EZH2 inhibitors and 
PI3K inhibitor all raised the mRNA expression of PI3K interacting protein 1 
(PIK3IP1), a negative regulator of PI3K by binding to the p110 catalytic subunit of 
PI3K and suppressing it activity.327 Combining copanlisib with GSK126 or EPZ-
6438 induced a higher expression of PIK3IP1 in Calu3, Sw1573 and all the 
BEAS2B lines (Figure 4.12a and 4.12b). To validate the use of this drug 
combination in vivo, we administered four treatment arms including vehicle, 
copanlisib, EPZ-6438 and copanlisib combined with EPZ-6438 (combo) to mice 
harboring Calu3 xenografts. IHC analysis confirmed that H3K27me3 was 
decreased in the EPZ-6438 and combo treated xenografts (Figure 4.13a). After 
10 days of treatment, tumor growth was significantly slower in copanlisib, EPZ-
6438 and combo treated mice compared with vehicle (Figure 4.13b). Importantly, 
combo treated xenograft tumors were also significantly smaller than the copanlisib 
or EPZ-6438 alone, demonstrating a collaborative effect of these two drugs in vivo. 
Together, these results reveal a promising combination therapy of EZH2 inhibition 









Figure 4. 9 EZH2 inhibition synergizes with PI3K inhibition in lung cancer cell 
lines in vitro 
 
(A) Immunoblots of indicated proteins in Calu3 and Sw1573 cells with vehicle, 
GSK126, EPZ-6438, copanlisib, GSK126+copanlisib and EPZ-6438+copanlisib, 
respectively. (B) Heatmap of Bliss synergy scores of GSK126 combined with 
copanlisib, EPZ-6438 combined with copanlisib in Calu3 and Sw1573 used to 
produce an average matrix. Overall Bliss scores with 95% confidence intervals 
were 4.7+/-2.2, 8.1+/-1.4, 2.6+-5.9, and 4.8+/-3.5, respectively. Most synergist 









Figure 4. 10 PIK3CA WT and E545K do not change sensitivity to GSK126 in lung 
epithelial cells 
 
Dose responses of the indicated BEAS2B cell lines treated with GSK126, 









                          
 
 
Figure 4. 11 EZH2 inhibition synergizes with PI3K inhibition in lung epithelial cells 
with or without PIK3CA mutation in vitro 
 
(a) Heatmap of Bliss synergy scores of GSK126 combined with copanlisib in the 
indicated BEAS2B cell lines used to produce an average matrix. Overall Bliss 
scores with 95% confidence intervals were 8.2+/-3.9, 10.3+-4.2, 5.5+-3.3, and 
6.8+-3.7, respectively.  Most synergist area Bliss scores were 13.5, 16.3, 11.1, and 
12.3, respectively. (b) Heatmap of Bliss synergy scores of EPZ-6438 combined 
with copanlisib in the indicated BEAS2B cell lines used to produce an average 
matrix. Overall Bliss scores with 95% confidence intervals were 7.1+-2.6, 5.7+-1.7, 
9.4+-3.4, and -5.6+-3.0, respectively.  Most synergist area Bliss scores were 9.35, 







Figure 4. 12 EZH2 inhibition and PI3K inhibition reduce PIK3IP1 expression 
 
(a) Relative mRNA expression of PIK3IP1 in Calu3 and Sw1573 cells with the 
indicated treatments. (b) Relative mRNA expression of PIK3IP1 with treatment of 
vehicle, GSK126, EPZ-6438, copanlisib, GSK126+copanlisib and EPZ-









Figure 4. 13 EZH2 inhibition cooperates with PI3K inhibition in lung cancer cells 
in vivo 
 
(a) Representative images of H3K27me3 IHC staining in the Calu3 xenografts with 
the indicated treatment. (b) Percentage of tumor growth relative to Day0 for 10 






4.6 Summary and discussion 
PI3K inhibitors in clinical trials did not show robust anti-tumor effect in lung 
cancer.316-318,328 This study shows that PIK3CA mutation is a moderate oncogene 
with weak transformation capacity compared with KRAS mutation, which suggests 
that cancer cells may not heavily rely on the PI3K pathway, especially when 
negative regulators such as PTEN are intact or bypath activation of PI3K 
downstream targets exist. This might be the reason why PI3K inhibitors have not 
been shown promising results in clinical trials. Similarly, other studies found 
PIK3CA-H1047R was also a weak oncogene on its own in breast cancer, but it 
could cooperate with other oncogenic lesions, such as partial loss of the tumor 
suppressor APC.329 Our research is the first time to describe the oncogenic 
property of PIK3CA E545K, the most prevalent mutation in lung cancer. 
Furthermore, there are some other therapies showing cooperative effect with PI3K 
inhibition, including combinations with receptor tyrosine kinase inhibitors, 
endocrine therapies, mTOR inhibitors, MEK inhibitors and DNA damaging 
chemotherapies.330 Discovery of novel combinatorial strategies may improve the 
efficacy of PI3K inhibitors in lung cancer. 
 
The mechanisms of PI3K inhibition synergizing with EZH2 inhibition need 
further study. We showed a possible mechanism that PI3K inhibition or EZH2 
inhibition alone could both increase the expression of PI3K negative regulator 
PIK3IP1, and combining these two strategies induced a more robust upregulation 
of PIK3IP1. It is consistent with the immunoblot result which showed copanlisib 
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combined with EPZ-6438 led to a lower phospho-AKT compared with copanlisib 
alone. However, such decrease in phospho-AKT was not observed in copanlisib-
GSK126 combined treatment. Thus, we could not exclude the possibility of 
GSK126-induced toxicity in this scenario. In the future, we propose to perform 
RNA-sequencings on the cells treated with the four arms to help discover other 
novel mechanisms to explain the synergy combining EZH2 inhibitor with PI3K 
inhibitor. 
 
The reason why PIK3CA E545K mutation generated LADC but not LSCC 
remains unknown. The result of adenocarcinoma formation was consistent with 
the cBioportal results that LADC harbored more PIK3CA mutations than amplified 
PIK3CA, while most of the LSCC samples had PIK3CA amplification, not PIK3CA 
mutations. PIK3CA mutation or amplification may have distinct molecular targets 
driving different programs of tumor initiating and progression. Such difference was 
also reported in HER-2 positive lung cancer.331 Mutation or amplification of PIK3CA 
may also transform different cells-of-origin, like AT2 cells or basal cells 
respectively, which requires further investigation in different stem or progenitor 
cells.332 PI3K pathway was also found to have important roles in embryonic 
development and cell fate determination.333 Therefore, understanding of such 






CHAPTER 5. EPIGENETIC STATE DETERMINES SENSITIVITY OF EGFR-
DRIVEN LUNG CANCER CELLS TO THERAPY 
5.1 Brief introduction 
Understanding the cellular and molecular origins of lung cancer will help 
define ways to prevent this deadly disease. Different stem or progenitor cells of 
adult lung reside throughout the trachea to the distal alveoli, including basal cells 
and club cells in the proximal airways, bronchioalveolar stem cells (BASCs) and 
alveolar type 2 (AT2) cells in the distal airways 213,229,230. Lung adenocarcinoma 
has been postulated to originate from club cells, AT2 cells or BASCs, while 
squamous cell carcinomas likely arise from basal cells 334-336. Experimental models 
have shown that given different oncogenes, lung cells can be more or less ‘fit’ to 
form fully malignant lesions 248,337,338.  However, the cellular origins for the majority 
of lung cancers have not been clarified yet. Determining common lung tumor 
origins may help us to understand how to prevent malignant transformation, and 
guide us to using appropriate therapeutics. 
 
Precision medicine options for lung cancer have greatly expanded in the 
past decade. Biomarkers encoded by genetic changes are currently the 
predominant tools for deciding precision medicine options.  However, epigenetic 
biomarkers, including markers of cell states, could add crucial additional 
predictions of drug responses. As an example, for lung adenocarcinoma there are 
at least three distinct reproducible subtypes that have been identified through 
transcriptomics approaches, and each of these subtypes may have not only 
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genetic, but also epigenetic determinants of drug response. 339 These three 
subtypes have been termed bronchoid, magnoid and squamoid.  From the 
perspective of lung epithelial cell types, squamoid may represent bronchiolar 
epithelial cells including SOX2+ secretory club cells or basal cells, while bronchoid 
may represent more distal alveolar type 2 cells. Bronchoid tumors tend to be more 
acinar and better prognosis, while squamoid have more solid pattern and worse 
prognosis. Magnoid tumors are characterized by high cell cycle and poorer 
prognosis. Transcriptionally distinct subtypes may provide an additional layer of 
guidance for prognosis or therapeutics in clinics. 
 
One of the most successful precision medicine options for lung cancer 
patients is targeting the epidermal growth factor receptor (EGFR) with drugs that 
inhibit the tyrosine kinase function of the activated protein 340. Gefitinib was the first 
EGFR inhibitor, followed quickly by erlotinib, but both inhibitors were plagued by 
development of drug resistance, in many cases through mutation of the T790M 
gatekeeper residue of EGFR 128,341.  Second generation irreversible and third 
generation mutant-selective inhibitors including afatinib, osimertinib and rociletinib 
were developed 342.  Most recently, the third generation TKI osimertinib has been 
moved to a first line agent for EGFR mutant lung cancer134. However, acquired 
resistance to osimertinib has also emerged in patients potentially resulting from 
EGFR mutations (C797S, G724S, L718Q), loss of T790M, pathway bypass 





Here we describe a model of EGFR-driven lung cancer and a method to 
develop tumors of distinct epigenetic states through the use of three-dimensional 
(3D) organotypic cultures. We discovered that EGFR mutation led to lung cancer 
with alveolar or bronchiolar features, which can originate from AT2 cells or BASCs, 
but not basal cells or club cells of the trachea.  We also demonstrate that these 
clones were able to retain their epigenetic differences through passaging 
orthotopically in mice, and crucially that they had distinct drug vulnerabilities that 
can be modulated through drug combinations. This work serves as a blueprint for 
exploring how epigenetics can be used to stratify patients for precision medicine 
decisions. 
 
5.2 The autochthonous LSL:EGFR T790M/L858R model develops lung 
adenocarcinoma in mice 
To interrogate the cell-of-origin for EGFR-driven lung cancer, we utilized a 
model generated by knocking in the human EGFR gene encoding protein with both 
T790M and L858R mutations (EGFR TL) into the Collagen1a1 (Col1a1) locus 
(Figure 5.1a). The EGFR TL mutations were used in the model because patients 
usually had L858R mutation firstly and acquired the second T790M mutation to 
become resistant to first or second generation TKIs. The resulting mice contain 
one Col1a1 locus that had been replaced with a lox-stop-lox cassette followed by 
the CAG promoter and a mutant EGFR gene. Cre-mediated deletion of the lox-
stop-lox site was accomplished by intranasal instillation of adeno-Cre virus, which 
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infects random cells from the proximal to distal airways. The median of the tumor-
free survival in this model was 107 days, 120 days for males and 107 days for 
females with no statistical difference between the males and females (Figure 
5.1b). The tumors that formed by intranasal adeno-Cre installation were almost 
exclusively alveolar type adenocarcinoma, with rare tumor types exhibiting 
bronchiolar features according to their immunofluorescence (IF) staining, although 
it is difficult to distinguish them by their histological morphologies (Figure 5.1C and 
5.2). Using IF staining, we demonstrated that majority of the tumors expressed the 
AT2 cell marker pro-surfactant protein C (proSPC), while rare tumors also had 
expression of club cell secretory protein (CCSP) or the bronchiolar transcription 
factor SOX2. It is similar with the previous study in EGFR TL mice, in which the 

















Figure 5. 1 The autochthonous LSL:EGFR T790M/L858R model develops lung 
cancer in mice 
 
(a) Schematic of mouse model with LoxP-mediated activation of EGFR 
T790M/L858R mutations. (b) Overall survival of mice of the indicated gender is 
graphed, n=7 male, n=13 female. (c) Representative H&E stained cross sections 












Figure 5. 2 The autochthonous LSL:EGFR T790M/L858R model develops lung 
adenocarcinoma with alveolar or bronchiolar features in mice 
 
Representative immunofluorescence staining of EGFR T790M/L858R 








5.3 Distal lung stem/progenitor cells efficiently undergo ex vivo malignant 
transformation by mutant EGFR 
Next, in order to understand if there are different cells in the normal lung 
epithelium that can serve as cells of origin for the EGFR-driven lung cancers, we 
used our in vitro transformation strategy 248.  Lungs and tracheas from non-tumor 
bearing mice were isolated and the cells were dissociated and sorted for Nerve 
Growth Factor Receptor (NGFR)+ basal cells of the trachea, NGFR- club cells of 
the trachea, Stem Cell Antigen 1 (Sca1/LY6A)+ BASCs of the distal lung and Sca1- 
AT2 cells of the distal lung (Figure 5.3a). FACS-isolated lung cells were then 
divided into two aliquots, one of which received Adeno-GFP control virus, and the 
other one received Adeno-Cre virus to activate mutant EGFR (Figure 5.3b). The 
cell populations were then plated into 3D Matrigel organotypic cultures which also 
contained neonatal lung mesenchymal endothelial cells as supporting cells 258. 
Organoids post viral infection were allowed to grow and then were passaged. 
Organoids from each cell population tolerated the activation of EGFR TL mutations 
and continued to grow. During passages, organoids derived from BASCs were 
manually subcloned into alveolar, bronchiolar and mixed cultures by their 
microscopic morphologies. Mixed BASCs had both alveolar and bronchiolar 
organoids (Figure 5.4). Then, the four subtypes of organoids infected by Ad-Cre 
virus were orthotopically injected to the lungs of immunocompromised mice to 
allow for further in vivo transformation. The mice started to show signs of lung 
tumors 8 months post transplantation of AT2 cells or BASCs, including the 
bronchiolar, alveolar and the mixed BASC organoids (Figure 5.5a). Only one 
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mouse developed a small tumor nodule from tracheal club cell-derived 
transplantation (Figure 5.5b).  None of the mice that received basal cell-derived 
organoids had tumors at sacrifice. Due to these differences, mice transplanted with 
distal lung (BASC and AT2) organoids had a significantly shorter lung-tumor free 
survival than the proximal lung/trachea (basal cell and club cell) organoid 
transplantation (Figure 5.5c).  Bronchiolar BASCs and AT2 cells formed tumors 
with a higher tumor burden than the other organoid types, although high 
heterogeneity existed among each mouse (Figure 5.5d).  
 
Next, we analyzed the histology of the transformed tumors to study whether 
the tumors maintained their original lineage properties during in vivo transformation. 
It showed that most of the BASCs and AT2 derived tumors formed alveolar tumors 
in vivo, with positive staining of alveolar marker SPC and barely any expression of 
bronchiolar markers CCSP, SOX2 or the basal cell marker KRT5 (Figure 5.6). 
Bronchiolar BASCs formed a small number of orthotopic bronchiolar tumor 
nodules, although majority of the other tumors displayed positive staining of 
alveolar lineage marker. It suggested that a large part of the bronchiolar BASCs 
underwent lineage switch to alveolar state during transformation, probably due to 
the impact of specific microenvironment in which it may be easier for alveolar cells 
to reside. Altogether, these results suggested that the AT2 cells and BASCs were 
the main cellular origins of EGFR mutant lung cancer, and these tumors retained 







Figure 5. 3 Schematic of cell-of-origin study in lung stem or progenitor cells 
 
(a) Schematic of sorted for NGFR+ basal cells of the trachea, NGFR- club cells of 
the trachea, Sca1/Ly6A+ BASCs of the distal lung and Sca1- AT2 cells of the distal 
lung. (b) Schematic of cell-of-origin study in lung stem or progenitor cells including 
FASC-sorting, in vitro propagation and adenovirus activation of EGFR, in vivo 














Figure 5. 4 BASC-derived EGFR-activated organoids form alveolar and 
bronchiolar architectures in 3D culture 
 
 









Figure 5. 5 Distal lung stem/progenitor cells efficiently undergo ex vivo malignant 
transformation by mutant EGFR 
 
(a) Tumor-free survival of immunocompromised mice with the indicated 
transplanted organoid types. (b) Tumor counts from each mouse with indicated 
organoid types transplanted. (c) Tumor-free survival of immunocompromised mice 





p<0.001 between organoids from distal lung (lung) and proximal lung (trachea) by 
Mantel-Cox log-rank test. (d) Tumor burden as percentage of total lung was 















Figure 5. 6 BASC and AT2 derived organoids develop ex vivo transformed 
tumors with distinct lineage features 
 
H&E and IF analysis of orthotopic transformed bronchiolar and alveolar tumors 








5.4 Different stem/progenitor cells drive distinct gene expression during 
malignant transformation 
In order to understand the deeper mechanisms of tumorigenesis and 
progression induced by EGFR TL mutation, we performed RNA-sequencings on 
the various stem/progenitor cell-derived organoids with Ad-GFP or Ad-Cre virus 
and also tumor cells after orthotopic transplant (Figure 5.7a). To make sure 
equivalent RNA samples were being compared, the transplanted tumors were 
dissociated and propagated in 3D Matrigel culture in vitro prior to RNA extraction. 
IF staining of the lineage markers showed that tumoroids from alveolar tumors 
highly expressed alveolar marker SPC with no or low expression of bronchiolar 
markers CCSP and SOX2, and the basal cell marker KRT5, while the bronchiolar 
tumoroids, which were only obtained from bronchiolar BASC-derived transplants, 
expressed in the opposite pattern (Figure 5.7b). This result suggest that tumor 
cells retain their intrinsic lineage properties when propagating in vitro. 
 
Hierarchical cluster analysis showed that post-transplant tumoroids 
clustered together, away from the pre-transplant organoids (Figure 5.8a). 
Intriguingly, tumoroids from an in vivo autochthonous tumor were transcriptionally 
closer to mixed BASC-derived and AT2-derived tumoroids. To understand the 
transcriptional alterations happened during the transformation by EGFR 
T790M/L858R mutation in vitro and in vivo, we compared the gene expression on 
the organoids with Ad-GFP or Ad-Cre virus infection and before or after 
transplantation. The Gene Set Enrichment Analysis (GSEA) demonstrated that 
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activation of EGFR mutations in distal lung cells led to significant enrichment of 
genes associated with epithelial-mesenchymal transition (EMT), Hedgehog 
signaling, TGF-β, KRAS and also EGFR pathways.  Activation of EGFR mutations 
in proximal lung/tracheal cells caused enriched hallmarks of KRAS, E2F targets, 
G2M checkpoints, MTORC1 and AKT pathways (Figure 5.8b). EGFR pathway 
was not significantly enriched in the proximal lung organoids after EGFR activation. 
Within the distal lung epithelia, BASC-derived Ad-Cre organoids generally had 
higher gene expression in MYC targets, E2F targets, interferon-α response, G2M 
checkpoints, mutant p53 and EGFR pathways and lower expression of EMT and 
vascular endothelial growth factor-A (VEGF-A) signatures than the AT2-derived 
Ad-Cre organoids (Figure 5.9a).  
 
Then, to further study the tumorigenic mechanisms during orthotopic 
transformation, we compared BASC- and AT2-derived tumoroids post-transplant 
with pre-transplant. Although the pre- and post-transplant samples were 
sequenced at different platforms, principal component analysis (PCA) did not 
detect obvious confounding variables separating these two platforms. GSEA 
results then indicated that the gene sets relevant to MYC targets, MTORC1 
signaling, DNA repair and deletion of RB were accumulated in post-transplant 
tumoroids than pre-transplant, while EMT, EGFR and KRAS upregulated gene 
signatures were less enriched (Figure 5.9b).  Genes repressed upon knockdown 
of EED and EZH2 in human fibroblasts were upregulated in post-transplant 
tumoroids, suggesting that enzymatic function of Polycomb Repressive Complex 
146 
 
2 (PRC2) may be increased during the orthotopic transplantation. These signaling 
pathways regulated during the in vivo transformation may serve as potential 
therapeutic targets combined with EGFR inhibition.  
 
Furthermore, to interrogate the difference between bronchiolar and alveolar 
tumors, we then compared the transcriptional phenotypes of bronchiolar tumoroids 
derived from BASCs with alveolar tumoroids from either BASCs or AT2 cells 
according to the expression of their lineage markers. GSEA results demonstrated 
that bronchiolar tumoroids had transcriptional enrichment in TNF-α, KRAS, 
mutated p53, EGFR, BMI1 deletion and PRC2 activity associated pathways than 
alveolar tumoroids (Figure 5.9c). Conversely, alveolar tumoroids expressed 
higher E2F targets and G2M checkpoint genes than bronchiolar. Together, these 
data displayed that in vitro activation of EGFR T790M/L858R mutations and in vivo 
orthotopic transformation drove distinct transcriptional landscapes in cells with 













Figure 5. 7 Schematic of RNA-sequencing analysis from different stages of 
organoids and tumoroids 
 
(a) Schematic of RNA-sequencing samples from organoids with indicated 
treatment. (b) H&E and IF analysis of AT2-derived alveolar and BASC-derived 







Figure 5. 8 Different stem/progenitor cells drive distinct gene expression during 
malignant transformation 
 
(a) Hierarchical clustering and dendsort plot using principal component analysis of 
the variability of gene expression of the indicated samples. (b) Bar plots of 
normalized enrichment scores of selected gene signatures enriched in Ad-Cre 
treated distal lung (left) or proximal trachea (right) organoids relative to Ad-GFP 






Figure 5. 9 AT2 and BASC derived EGFR-mutant cells are transcriptionally 
different 
 
(a) Bar plots of normalized enrichment scores of selected gene signatures 
enriched in BASC-derived organoids relative to AT2-derived Ad-Cre treated 
organoids, with FDR q-values indicated outside the end of bars. (b) Bar plots of 
normalized enrichment scores of selected gene signatures enriched in tumoroids 





values indicated outside the end of bars. (c) Bar plots of normalized enrichment 
scores of selected gene signatures enriched in bronchiolar tumoroids relative to 


















5.5 Bronchiolar and alveolar tumoroids respond to therapies differentially 
Next, to interrogate whether tumors with different cell fates have distinct 
sensitivities to therapies, especially tyrosine kinase inhibitors (TKIs), we performed 
dose-response assessment on the bronchiolar and alveolar 3D tumoroids. First, 
we confirmed the expression of lineage markers of these tumoroids by RT-qPCR. 
It showed BASC-derived bronchiolar (BASC-B) tumoroids had significantly lower 
expression of alveolar marker Sftpc, higher expression of club cell marker Scgb1a1 
and proximal lung epithelial markers including Sox2, Trp63, Krt5 and Foxj1 than 
the AT2-derived alveolar (AT2-A) tumoroids (Figure 5.10a). Intriguingly, BASC-
derived alveolar (BASC-A) tumoroids from alveolar tumors expressed both 
Scgb1a1 and modest Sftpc, together with expression of the proximal airway 
lineage markers Trp63 and Krt5. It suggested that BASC-A cells may be in a mixed 
lineage state, keeping the dual-potential to become alveolar and bronchiolar cells 
during passages. Consistently, BASC-A contained morphologically bronchiolar, 
alveolar and mixed tumoroids (Figure 5.10b). 
 
Next, we tested first generation TKI erlotinib, second generation TKI 
afatinib, third generation TKIs osimertinib and rociletinib, pan-receptor tyrosine 
kinase (RTK) inhibitor Dovitinib, HDAC6 inhibitor Ricolinostat and BCL-2 inhibitor 
Venetoclax on AT2-a, BASC-A and BASC-B tumoroids. Overall, tumoroids had 
lower IC50 values for third generation TKIs than the first and second generation 
TKIs (Figure 5.11). Interestingly, it showed that AT2-A and BASC-A tumoroids 
were significantly more sensitive to third generation TKI rociletinib than BASC-B 
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tumoroids in in vitro 3D culture (adjusted p=0.02, and adjusted p=0.0036, 
respectively, Figure 5.12). BASC-B tumoroids also had 2.5-fold higher IC50 to 
osimertinib than AT2-A. Similar results were observed in EGFR TL-driven lung 
cancer previously, which the peripheral tumors were relatively more sensitive to 
HKI-272, an irreversible EGFR inhibitor, than the bronchial tumors 343.  No 
significant difference of IC50 values was observed in these tumoroids to afatinib. 
Expectedly, erlotinib did not manifest a potent therapeutic effect on these 
tumoroids with T790M mutation. On the contrary, BASC-B were more responsive 
to dovitinib than the AT2-A tumoroids. Venetoclax also harbored a lower IC50 in 
BASC-B than BASC-A and AT-2 tumoroids. Since the alveolar and bronchiolar 
tumoroids had the same mutations, these results suggested that different 
epigenetic states affected the drug vulnerabilities to TKIs and other therapies. 
 
Lastly, we aimed to detect potential therapies which could combine with and 
improve the therapeutic effect of TKIs in the relatively insensitive tumors. 
According to the GSEA results from Figure 5.9b comparing post-transplant 
tumoroids with pre-transplant organoids which indicated that MYC, mTOR and 
EZH2-target pathways were enriched during the in vivo transformation, we then 
tested osimertinib combined with EZH2 inhibitor EPZ-6438/tazemetostat, BET 
inhibitor JQ1 which was proved to suppress MYC function, or PI3K/AKT/mTOR 
pathway inhibitor copanlisib on EGFR-mutant tumoroids and lung cancer lines 344-
346. It showed that JQ1 and copanlisib combined with osimertinib led to significantly 
more potent inhibitory effect than using these drugs alone in BASC-A tumoroids 
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(Figure 5.13a). EPZ-6438 combined with osimertinib also induced a lower cellular 
survival than EPZ-6438 alone, but not significantly lower than osimertinib alone. In 
the previous studies, EZH2 inhibitor has been observed to reverse gefitinib 
resistance in EGFR-wildtype lung cancer and synergize with HER2-targeted 
breast cancer treatment, but also showed conflicting results of conferring 
resistance to gefitinib in lung cancer347-349. It has been reported that irreversible 
TKI synergized with mTOR inhibitor rapamycin in peripheral and bronchial EGFR 
TL tumors 343.  PI3K-AKT-mTOR inhibitor was also shown to sensitize lung cancer 
cells to or overcome resistance to EGFR-TKIs 350-355. BET inhibition was reported 
to delay the acquired resistance to anti-EGFR antibody in head and neck 
squamous cell carcinoma, and synergize with anti-HER2 TKIs in lung cancer and 
breast cancer as well 356-358. Therefore, we verified these synergistic effects in 
human cell lines PC9-GR4 and H1975, which both possess EGFR T790M 
mutation. H1975 also had EGFR L858R mutation. The synergy matrix of 
osimertinib combined with EPZ-6438 or copanlisib both displayed vigorous 
synergist effect in PC9-GR4 and H1975 (Figure 5.13b). JQ1 also had synergy with 
osimertinib in H1975 but not in PC9-GR4, suggesting that PC9-GR4 cell line 
possibly harbors mutations antagonistic towards BET inhibition. Together, these 
data shed light on promising therapeutic combination with third generation TKIs in 











Figure 5. 10 Bronchiolar and alveolar tumor tumoroids differ in lineage markers 
and morphologies 
 
(a) Relative mRNA expression of lineage genes in the indicated mouse 3D 
tumoroids determined by RT-qPCR, n=3 or 4 technical replicates for each 
genotype. (b) Representative bright field images of the indicated 3D tumoroids 










 Figure 5. 11 Bronchiolar and alveolar tumor tumoroids have distinct IC50 to 
therapies 
 






Figure 5. 12 Bronchiolar and alveolar tumoroids respond to therapies 
differentially 
 
Dose responses to drugs osimertinib, rociletinib, afatinib, dovitinib, ricolinostat and 









   
 
Figure 5. 13 Third generation TKI osimertinib synergizes with EZH2 inhibition, 
BET inhibition and PI3K inhibition in lung cancer cells 
 
(a) Percentage of survival of BASC-A tumoroids with the indicated treatments 
compared to control.  (b) Heatmap of Bliss synergy scores of osimertinib combined 
with EPZ-6438, copanlisib and JQ1 in H1975 (left) 2D cultures with 3 technical 
replicates used to produce an average matrix. Overall Bliss scores with 95% 
confidence intervals were 1.36+/-3.82 for osimertinib+EPZ-6438, 3.36+/-3.56 
osimertinib+copanlisib, and 7.82+/-2.49 osimertinib+JQ1.  Most synergist area 
Bliss scores were 13.20 for osimertinib+EPZ6438, 9.06 for osimertinib+copanlisib, 




combined with EPZ-6438, copanlisib and JQ1 in PC9-GR4 (right) 2D cultures with 
3 technical replicates used to produce an average matrix. Overall Bliss scores with 
95% confidence intervals were 11.6+/-2.6 for osimertinib+EPZ-6438, 9.18+/-1.79 
osimertinib+copanlisib, and -9.1+/-1.43 osimertinib+JQ1.  Most synergist area 
Bliss scores were 16.08 for osimertinib+EPZ6438, 17.15 for 




























5.6 Summary and discussion 
In our model system, most of the transplanted and autochthonous tumors 
are alveolar. Even the bronchiolar BASCs formed mainly alveolar tumors. However, 
in the similar EGFR TL mouse model, the bronchiolar tumors were not such rare 
343. The reason behind the difference might be because in our mouse model the 
EGFR TL mutations were inserted into the collagen1a1 locus. The differentially 
expressed genes of RNA-seq data indicated that genes related to various types of 
collagen proteins were more frequently expressed in the alveolar cells than the 
bronchiolar cells, possibly fostering a collagen-rich microenvironment friendly for 
EGFR-mutant tumors to propagate. It may internally motivate the switch of 
bronchiolar BASC organoids to alveolar tumors during in vivo transformation. Also, 
interestingly, the tumor burdens of bronchiolar-derived tumors were larger than the 
alveolar-derived tumors. It is known that both club cells and BASCs can give rise 
to alveolar cells 230,359,360. Besides, some research demonstrated that AT2 cells 
might not be the major contributor of the regeneration of lung epithelium after 
bleomycin injury, while CCSP-expressing cells may play a significant role in this 
process 230,361-363. It suggested that BASCs possessed a potent potential of 
alveolar cell reconstruction. 
 
We also discovered that basal and club cells were unable to yield 
transplantable organoids when EGFR TL mutation was activated ex vivo. As lung 
squamous cell carcinoma is proposed to be originated from basal cells, it implied 
that EGFR-mutant squamous cell carcinomas might be derived from trans-
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differentiation of lung adenocarcinoma 334. However, the mechanism of why basal 
and club cells could not develop in vivo tumors needs further study. It might be 
because EGFR TL mutation drove mainly alveolar tumors, the cell type which 
basal and club cells could not directly give rise to. Moreover, according to the 
GSEA results, the basal and club cells did not significantly upregulate EGFR 
signaling pathway when EGFR TL mutations were activated by Ad-Cre virus, which 
might potentially prevent their further tumorigenesis in vivo. 
 
The dose curve assays showed that bronchiolar and alveolar tumors 
responded differentially to TKIs and other therapies. Especially, the third 
generation TKI osimertinib and rociletinib targeting T790M gatekeeper mutation 
were both more effective in the AT2-deived alveolar tumoroids than the BASC-
derived bronchiolar tumoroids. One possible theory is that bronchiolar and alveolar 
cells possess different compositions of EGFR homo- and hetero-dimers, so that 
they have different sensitivities to reversible, irreversible, and mutant-selective 
TKIs 343. According to our GSEA results, it is also possibly due to that EGFR 
signaling pathway was more enriched in the bronchiolar tumoroids than the 
alveolar ones. So, the bronchiolar cells might require higher dose of osimertinib 
and rociletinib to achieve the same level of EGFR repression. However, its clinical 






CHAPTER 6. SUMMARY AND FITURE DIRECTIONS 
The projects above studied different aspects of epigenetic regulations in 
non-small cell lung cancer. Chapter 3 demonstrated the dual effect of EZH2 by 
using GEMMs which showed Ezh2 haplo- and full-insufficiency lead to divergent 
phenotypes in KRAS+/Trp53-null lung ADC. Pharmacological inhibition of BET 
proteins or H3K27 demethylases impeded tumor growth preferentially in PRC2-
deficient lung tumors in vitro and in vivo. Biochemical and transcriptional analysis 
revealed PRC2 ablation-induced FOXP2 enrichment promotes lung tumor 
stemness and migratory potency, partially phenocopying the effect of Ezh2 
knockout in GEMMs. Moreover, FOXP2 could be attenuated by BET inhibitor JQ1. 
This study promotes a profound understanding of the PRC2 complex in lung 
cancer, which may be important for the use of EZH2 inhibitors in clinics. It also 
provides a therapeutic combination of EZH2 inhibition with BET inhibition in lung 
cancer patients. In the future, we will do ChIP-seq analysis on the cells with EZH2 
deletion on H3K27me3 and FOXP2 to understand the roles of epigenetic 
regulators and transcription factors in this scenario. Moreover, the altreations of 
immune microenvironment in EZH2 deleted lung cancer need further 
characterization. Preliminary results from our other studies in EZH2 inhibitor 
combined with immunotherapies PD-1 inhibitor showed promising effects in lung 
squamous cell carcinoma. However, immune system-related and tumor cell-
intrinsic mechanisms still need further investigation. 
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Chapter 4 starts from an interesting discovery that PIK3CA-mutant 
or amplified lung cancer cells were more sensitive to EZH2 inhibitor GSK126. 
Then we characterized PIK3CA E545K, the most common mutation in lung cancer, 
harbors a modest transformation capacity along with p53 loss in lung epithelial 
cells, and can drive lung adenocarcinoma formation autochthonously. 
Furthermore, we showed that EZH2 inhibition synergized with PI3K inhibition in 
human cancer cells in vitro and importantly in vivo. Given that PI3K inhibitor alone 
did not have promising therapeutic effects in clinical trials, this study sheds light on 
a potentially robust combinatorial therapy for patients with PIK3CA mutated or 
amplified lung cancer. Mechanistically, we show that PIK3IP1, the negative 
regulator of PIK3CA, may play a part in such synergy. However, further studies of 
RNA-sequencing data on these cells will help us understand the pivotal 
mechanisms in addition to PIK3IP1. Next, we plan to repeat copanlisib and 
tazemetostat combination treatment in other xenografts and also Pic3ca/p53 
mouse models, and if they show encouraging results, we can try to translate it into 
clinical trials. 
We also studied the cancer stem cells and their relativeness to treatments 
in Chapter 5. Firstly, we describe a model of lung cancer with two clinically pivotal 
EGFR mutations T790M and L858R, and a method to develop tumors of distinct 
epigenetic states through three-dimensional (3D) organotypic cultures. We 
discover that EGFR T790M/L858R mutations led to lung cancer with alveolar or 
bronchiolar features, which can be originated from AT2 cells or BASCs, but not 
basal cells or club cells of the trachea. These clones were able to retain their 
163 
 
epigenetic differences through passaging orthotopically in mice, and crucially that 
they had distinct drug vulnerabilities, especially EGFR-TKIs, the most successful 
targeted therapy strategy in lung cancer. This work paves road for exploring how 
stem cell origins and epigenetic states can be used to stratify patients for precision 
medicine decisions. In the future, we will query more clinical data and confirm 
whether the alveolar or bronchiolar subtypes of lung cancer patients, an apparent 
pathological or molecular difference basically neglected in clinics, do have 
differential responses to EGFR-TKIs and other therapies. The cellular origins of 
lung cancers with other mutations like PIK3CA can also be similarly investigated, 
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